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GENERAL INTRODUCTION 
Neurologie differential diagnosis is principally based on localisatory or 
anatomic criteria. The result of clinical neurologic investigation is generally a 
localisatory diagnosis, and a putative causal diagnosis. In many cases diagno-
sis is verified during a patient's lifetime by the course of the illness, by 
neuroradiologic and electrophysiologic investigations, and by biochemical 
studies. In several neurologic disorders the clinical diagnosis can be verified 
definitely only at autopsy. For instance, to date the diagnosis of "Progressive 
Infantile Poliodystrophy (Alpers' disease)" can only be confirmed at au-
topsy. 
In recent years definite diagnosis of several disorders has become possible by 
means of new methods of investigation in biochemical research. For instance, 
the biochemical defect of several so-called inborn errors of metabolism has 
become known. When demonstrating a biochemical or enzymatic defect a 
new criterium of differential diagnosis is introduced. 
Biochemical studies on enzymatic defects are indicated in disorders where 
the pathogenesis is still unknown, and especially in those disorders in which 
an autosomal recessive inheritance has been demonstrated. 
Specified enzymatic studies must be indicated from clinical, radiologic, 
electrophysiologic, and above all from routine biochemical studies. Investiga-
tions of serum, urine and cerebrospinal fluid (CSF) may suggest a defect in 
specific enzymatic systems. 
Elevated levels of lactate and pyruvate in serum and in CSF may indicate a 
disturbance of the pyruvate metabolism, namely pyruvate oxidation, the 
citric acid cycle and the respiratory chain. These enzymatic systems are 
involved in the cellular energy metabolism. 
The Department of Child Neurology and the Department of Clinical Neuro-
chemistry of the Institute of Neurology, and the Laboratory of Clinical 
Biochemistry of the Institute of Pediatrics of the Radboud University Hospi-
tal, Nijmegen, have had fairly lengthy experience of the study and interpreta-
tion of normal and elevated levels of lactate and pyruvate in serum and CSF 
of children with various disorders. 
This study contains a report of the clinical, morphologic and biochemical 
investigations in children with a progressive disorder of the cerebral gray 
matter, with increased levels of lactate and pyruvate in serum, urine and/or 
CSF. Histopathologic studies of brain tissue in these children revealed the 
characteristics of progressive infantile poliodystrophy. 
Chapter 1 summarizes the literature on progressive poliodystrophy. Special 
attention is given to the data from literature referring to the pathogenesis of 
the disorder. 
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Chapter 2 gives a survey of the cerebral energy metabolism, namely pyruvate 
oxidation, the citric acid cycle and the respiratory chain. Some neurologic 
diseases are mentioned, in which disturbances of the pyruvate metabolism 
have already been demonstrated. Concluding the first two chapters, a 
working hypothesis is formulated with respect to the pathogenesis of progres-
sive poliodystrophy. 
In chapters 3-6 the case reports of five patients are presented. In these 
patients with demonstrated progressive poliodystrophy, deficiencies were 
demonstrated in pyruvate oxidation, in the citric acid cycle and in the 
respiratory chain. The case reports have been published previously in several 
neurologic journals. 
Chapter 7 summarizes the literature data and the patient studies. Conside-
ring the clinical, morphologic and biochemical findings a final conclusion is 
formulated, including a hypothesis on the pathogenesis of progressive polio-
dystrophy. Moreover, the consequences of these findings are discussed, with 
respect to various aspects of the disease. 
This study does not pretend to be a presentation of new clinical, morphologic 
or biochemical investigations, although it does aim to make a fundamental 
contribution to the knowledge of progressive poliodystrophy and to neurolo-
gic differential diagnosis, through the use of recent methods of clinical, 
morphologic and biochemical investigations, and by correlating the results of 
these methods of investigation. 
16 


CHAPTER 1 
LITERATURE ON PROGRESSIVE POLIODYSTROPHY 

INTRODUCTION 
This chapter gives a survey of the literature on progressive poliodystrophy, 
with specific emphasis on the pathophysiologic concept of this disorder. 
Special attention will therefore be paid to the relation of the following 
aspects of this disorder: clinical signs, genetic studies, pathologic findings, 
and biochemical investigations. 
During this study of progressive poliodystrophy the cellular energy metabo-
lism appeared to be of great importance. We will therefore look particularly 
at those studies in the literature which report on biochemical aspects of 
carbohydrate metabolism or on morphologic investigations of mitochondria. 
SURVEY OF CASE HISTORIES IN THE LITERATURE 
ALPERS' FIRST DESCRIPTION 
Alpers2 in 1931 described for the first time the clinical entity of poliodys-
trophy, reporting the case history of a 3-month-old girl. The infant was 
admitted to the hospital because of generalized seizures. The girl's prenatal, 
natal and postnatal history was unremarkable. The family history showed no 
abnormalities. 
The illness was rapidly progressive, with increasing loss of consciousness, 
irregular respiration, recurrent convulsions, attacks of general rigidity of the 
musculature, blindness and strabismus. The girl died at the age of four 
months. 
Alpers gave an extensive description of pathologic findings in the central 
nervous system, which can be summarized as follows. Gross examination of 
the brain showed no abnormalities. Histopathologic studies of the brain, 
however, revealed some remarkable findings. Focal areas with a necrotic 
aspect were seen diffusely spread throughout the cerebral cortex, the basal 
ganglia and the brainstem nuclei. These areas presented with severe loss of 
nerve cells and a degenerative aspect of the still persisting neurons, with an 
irregular, moth-eaten cytoplasm in which no Nissl substance could be made 
out. Moreover, an extensive astrocytosis, and increase and dilatation of 
capillaries was observed. 
Alpers noted another, in his opinion equally important, abnormality: he 
described the presence of subependymal germinal foci associated with migra-
ting neuronal elements in the cerebral white matter. 
Alpers presented his report as a description of a new clinical entity, under the 
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title "diffuse progressive degeneration of the gray matter of the cerebrum". 
In his comment Alpers distinguished structural changes and developmental 
changes. He stressed the strict confinement of the structural pathologic 
features to the gray matter of the cortex and basal ganglia. In accordance 
with Jakob27 Alpers described this degenerative process as an incomplete 
necrosis due to vascular or toxic injury. Alpers interpreted the latter abnor-
malities in the subependymal regio and in the cerebral white matter as a sign 
of a developmental defect. 
OTHER CASE REPORTS IN THE LITERATURE 
Before Alpers' description a similar clinical and pathologic entity was repor-
ted by Freedom20 and by Rusk and Nixon.44 Subsequently approximately 90 
cases of the disorder have been reported (table 1). 
The literature on progressive poliodystrophy was reviewed respectively by 
Ford et al,19 Alpers,3 Greenhouse and Neubuerger,21 Jellinger and Seitelber-
ger,30 Huttenlocher et al26 and Partouche.40 
Studies involving mitochondrial dysfunction in progressive poliodystrophy 
were published by Suzuki and Rapin,50 Sandbank and Lerman,45 Shapira et 
al,46 Hart et al23 and Partouche;40 the last case was also reported by David et 
al14 and by Tommasi et al.51. In this study special attention will be paid to 
those reports which deal in detail with mitochondrial dysfunction. 
DEFINITION, CLASSIFICATION AND NOMENCLATURE 
In the literature no precise definition of the disorder was proposed. Like 
Alpers2 most authors mentioned the cortical abnormalities as the most 
distinctive features of the disorder. However, neither the pathologic findings 
nor the clinical signs are specific to this disorder alone. Progressive poliodys-
trophy may be suspected when clinical signs point to a progressive disorder of 
cerebral gray matter; deficiencies, infectious diseases, intoxications, vascular 
pathology and inborn errors of metabolism must be excluded. Suspected, 
progressive poliodystrophy can only be proved by extensive histopathologic 
study of the total brain. The disorder is characterized by neuronal degenera-
tion, astrocytic proliferation, dilatation and proliferation of capillaries in 
cerebral gray matter. In general, the diagnosis can be confirmed at autopsy. 
About 90 cases of progressive poliodystrophy have been reported as a 
separate entity. Nevertheless, in many neuropathologic and neurologic hand-
books and textbooks this condition is described in several ways. In most 
handbooks and textbooks the disease is reported in the group of degenerative 
22 
Table 1. Patients with progressive pollodystrophy previously reported In the llteratute. 
Case 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
Author 
Freedom20 1927 
Rusk and Nixon4 4 1927 
Rusk and Nixon4 4 1927 
Jakob28 1930 
(quoting Somoza) 
Alpers2 1931 
Walthard56 1931 
Walthard561931 
Wohlwill59 1931 
Rösch4 3 1932 
Diamond1 5 1934 
Levin35 1936 
Christensen and 
Krabbe10 1949 
Fattovich18 1950 
Ford et al19 1951 
Kramer33 1953 
Palinsky et al39 1954 
Wolf and C o w e n " 
Wolf and C o w e n " 
Wolf and C o w e n " 
Wolf and C o w e n " 
Wolf and C o w e n " 
Wolf and Cowen" 
Wolf and C o w e n " 
Wolf and C o w e n " 
Smulders48 1956 
Jervis31 1956 
Mattyus37 1957 
Liu and Sylvester16 
Liu and Sylvester36 
Couville12 1960 
Couville12 1960 
Couville12 1960 
Courville12 1960 
Courville12 1960 
Bebin5 1962 
Verhaart54 1962 
'54 
'54 
'54 
'54 
'54 
'54 
'54 
'54 
'60 
'60 
Sex 
F 
F 
M 
M 
F 
F 
F 
F 
F 
M 
F 
M 
M 
F 
F 
M 
F 
F 
M 
F 
F 
M 
M 
M 
F 
F 
F 
M 
M 
M 
M 
M 
F 
M 
F 
F 
Age at onset 
(yrs, mos) 
3 
2 
0.10 
0 
0.3 
3 
13 
2 
1.3 
0,УЛ 
0 
0.6 
0 
0.6 
0.4 
0.3 
0.3 
0.5 
3 
1.11 
0 
1 
1.6 
6 
14 
1.3 
3 
0 
0 
0 
0.5 
0 
0 
0 
12 
0.9 
Age at death Duration of illness 
(yrs, mos) 
19 
3 
1.6 
0.9 
0.5 
3 
13 
2 
1.3 
О.З'Л 
0.9 
3 
10 
1.3 
4 
1.3 
2.9 
1.5 
4.9 
2.1 
3.3 
1.2 
27 
7 
16 
5.5 
3.3 
3.2 
1.4 
2 
3 
0.11 
0.4 
1.4 
14 
0.9 
(yrs) 
16 
1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
2 
10 
< 1 
3 
1 
2 
1 
1 
< 1 
3 
< 1 
25 
1 
2 
4 
< 1 
3 
1 
2 
2 
< 1 
< 1 
1 
2 
< 1 
23 
Case Author Sex Age at onset Age at death Duration of illness 
(yrs, mos) (yrs, mos) (yrs) 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
Verhaart54 1962 
Blackwood6 1963 
Blackwood6 1963 
Blackwood6 1963 
Blackwood6 1963 
Blackwood6 1963 
Dreifuss and 
Netsky16 1964 
Greenhouse and 
Neubuerger21 1964 
Christensen and 
H0jgaardn 1964 
Christensen and 
Htfjgaard11 1964 
Christensen and 
H0jgaard11 1964 
Christensen and 
H0jgaard11 1964 
Christensen and 
Hujgaard11 1964 
Christensen and 
Hujgaard11 1964 
Christensen and 
Hujgaard11 1964 
Ebels17 1964 
Alberca-Serrano 
et al1 '65 
Ulrich and Cunz52 '66 
Wefring and 
Lamvik58 1967 
Wefring and 
Lamvik58 1967 
Crompton13 1968 
Laurence and 
Cavanagh34 1968 
Laurence and 
Cavanagh34 1968 
Laurence and 
Cavanagh34 1968 
Laurence and 
Cavanagh34 1968 
M 
M 
F 
F 
M 
F 
M 
F 
F 
M 
M 
M 
F 
F 
M 
F 
F 
F 
F 
M 
M 
F 
F 
M 
M 
0 
0.8 
1 
0.11 
0.8 
0.2 
3 
4 
0.6 
0.2 
0.2 
1.7 
1 
0.7 
0.5 
0.9 
< 2 
0.3 
1 
1.3 
0.5 
0.2 
0.6 
0 
0.3 
0 
3.6 
? 
1.8 
0.10 
1 
3.6 
4.6 
1 
0.6 
0.5 
3 
4 
6 
2.9 
1.9 
2.6 
3.5 
1.7 
? 
3.5 
0.10 
0.8 
0.3 
1.9 
< 1 
2 
? 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
< 1 
1 
3 
5 
2 
1 
1 
3 
< 1 
? 
3 
< 1 
< 1 
< 1 
1 
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Case Author Sex Age at onset Age at death Duration of illness 
(yrs, mos) (yrs, mos) (yrs) 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
86 
Klein and 
Dichgans31 1969 
Klein and 
Dichgans31 1969 
Suzuki and Rapin50 '69 
Jellinger and 
Seitelberger30 1970 
Jellinger and 
Seitelberger30 1970 
Jellinger and 
Seitelberger30 1970 
Bruno9 1971 
Sandbank and 
Lerman45 1972 
Sandbank and 
Lerman45 1972 
Sandbank and 
Lerman45 1972 
Hopkins and 
Turner25 1973 
Guidugli et al22 '73 
Skullerud et al47 '73 
Janota29 1974 
Janota29 1974 
Janota29 1974 
Shapira et al46 1975 
Shapira et al46 1975 
Huttenlocher et 
al26 1976 
Huttenlocher et 
al26 1976 
Huttenlocher et 
al26 1976 
Tommasi et al51/ 
Partouche40 1977 
Tommasi et al51/ 
Partouche40 1977 
Hart et al23 1977 
Hart et al23 1977 
F 
F 
F 
F 
F 
M 
F 
F 
M 
M 
F 
M 
F 
M 
M 
M 
F 
M 
F 
M 
F 
M 
F 
F 
M 
5 
13 
0.3 
0.6 
1 
2.4 
9 
0.1 
0.1 
0.1 
1 
8 
0 
0.9 
0.1 
2.11 
4 
3 
2.6 
2 
2 
0.2 
0.3 
7 
9 
6 
13 
3.6 
7.6 
6.3 
2.10 
14 
1.3 
0.6 
1.6 
5.1 
9 
0.10 
1.4 
1.3 
3.5 
16 
10 
3 
2.1 
2.3 
3.6 
3.7 
18 
7 
1 
< 1 
< 3 
7 
5 
< 1 
5 
1 
< 1 
1 
4 
1 
< 1 
< 1 
1 
< 1 
12 
7 
< 1 
< 1 
< 1 
3 
3 
11 
? 
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disorders of the central nervous system;7'24·41,551857 progressive poiiodys-
trophy is classified as a degeneration of cerebral gray matter of unknown 
etiology and without specific cause. In the Handbook of Clinical Neurology53 
the disease is not presented as a separate entity, but is considered as part of 
the entity of "diffuse cerebral degeneration". 
The ambiguity which exists in the classification of this disorder is likewise 
found in the nomenclature. Most often a disorder of the cerebral gray matter 
is suggested: "diffuse degeneration of cerebral gray matter",2,3,19 "diffuse 
cortical sclerosis",20 "poliodystrophia cerebri progressiva infantilis".10 In 
other publications a more general nomenclature was chosen: "spongy glio-
neuronal dystrophy",30,32 "diffuse cerebral degeneration in infancy",6,26 "pro-
gressive cerebral poliodystrophy".21 
THE CLINICAL MANIFESTATIONS OF PROGRESSIVE POLIODYSTROPHY 
CLINICAL SIGNS 
The clinical manifestations of progressive poliodystrophy are not highly 
specific. The clinical signs are comparable to those in most of the disorders of 
cerebral gray matter. 
The prominent signs are psychomotor retardation, epileptic manifestations, 
myoclonus and severe motor disability. Ophthalmologic abnormalities, deaf-
ness and neurovegetative disorders are also frequently observed. 
In general, the prenatal, natal and postnatal histories are described as 
unremarkable. In many cases the first manifestation of the disorder occurred 
rather suddenly in early life. Epileptic manifestations were frequently the 
first clinical sign. Major epilepsy was observed, as were partial seizures in 
various appearances. Myoclonus seems to be a separate main sympton of the 
disease. Myoclonic jerks frequently occurred independent of the epileptic 
manifestations. Progressive mental deterioration was observed in all cases. 
Sometimes the initial development of the children was quite normal. Howe-
ver, in most children developmental retardation in early life was characteris-
tic. Most children had severe motor disability. Spasticity and hypotonia were 
present. In many cases exaggeration of the deep reflexes was observed, the 
plantar responses often became extensor. Less frequently ataxia and extrapy-
ramidal symptoms were noted. Various other abnormalities were also seen: 
ophthalmologic manifestations (i.e. optic atrophy, blindness, retinitis pig-
mentosa, impairment of ocular movement, and sometimes hemianopia), 
deafness, and defects of neurovegetative regulation (e.g. gastro-intestinal 
problems such as vomiting, diarrhoea, constipation). 
26 
Many authors6111316·26·29·30·32·34·39'44·45·46·48·60 indicated that the first symptoms 
of the disease were seen after periods of psychic or physical stress (infections, 
exertion, etc.). Such situations also seemed to provoke relapses of the 
disorder. Klein and Dichgans32 formed the hypothesis that a genetic predis-
position towards the disorder would be manifest after some illnesses. 
Although this phenomenon appears to be an important feature in progressive 
poliodystrophy, deterioration after stressful situations was mentioned in only 
some of the cases. However, because such a feature is not always requested 
in a general anamnesis, presumably not all investigators noticed this pheno-
menon. Provocation of the symptoms of progressive poliodystrophy after 
stress was mentioned several times in the studies dealing with aspects of 
mitochondrial dysfunction in the disorder, namely three times after a respira-
tory infection,45,46 and in two cases after exercise.46 
HEREDITY 
Progressive poliodystrophy is generally inherited as an autosomal recessive 
trait. In McKusick's "Mendelian Inheritance in Man"38 the disorder is 
mentioned as *20370. 
In the literature 43 cases have a positive family history, in the other 43 cases 
no family data were reported. In 12 cases only one single sib of a family was 
described; in these descriptions there was merely a reference to other 
patients within the same family. The other 31 patients with positive family-
history belonged to 15 families, in which every time two or three cases were 
reported. In one case, twins (two boys; whether they were identical twins was 
not stated) suffered from the disorder.11 No family was described with 
patients in more than one generation. 
It is not possible to quote the number of normal sibs in the families with more 
than one case; in general only the affected sibs were mentioned. In the group 
of patients the distribution of sexes is almost equal: 47 girls and 39 boys. 
These data on the family histories of patients, and on the distribution of sexes 
are in accordance with an autosomal recessive inheritance pattern. 
AGE DISTRIBUTION 
Within the group of patients there is a marked variation in the age distribu-
tion of the children. Ford19 was the first to draw attention to the age 
distribution of the children suffering from progressive poliodystrophy. Des-
cribing a group of 8 patients he distinguished between an infantile and a 
juvenile expression. According to Ford the infantile form manifests in early 
27 
number 
of 
patients 
f V v ì 
1 49 
12 
7 
6 
AGE AT ONSET 
2 
1 Ι ι Ι ι I 1 
2 
4 
1 2 3 4 5 6 7 8 9 10 >10 
Age (yrs) 
number 
of 
patients 
16 
18 
AGE AT DEATH 
1 2 3 4 5 6 7 θ 9 10 >10 
Age (yrs) 
number 
ot rfl 
patients ' 32 DURATION OF ILLNESS 
| First signs < 3 y r s 
f J First signs s 3 y r s 
2 
5 
6 
>5 yrs 
Figure 1. Age at onset, age at death, and duration of Illness In patients with progressive 
pollodystrophy In the literature. 
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childhood and has a very rapidly progressive course. Most of these children 
die within the first year of life, but some children survive for two or three 
years. The juvenile form is characterized by a manifestation of the first 
symptoms at about five years; in the patients described by Ford himself the 
age varied between three and six years. This juvenile form of the disease has 
a less progressive course; the children mentioned by Ford died at between 6 
and 19 years of age. 
These two groups can also be distinguished in the literature on progressive 
poliodystrophy (table 1). However, the separation between the two is not as 
distinct as in the patients reported by Ford. In 68 of the 86 children described 
in the literature the first symptoms of the disease were reported before 3 
years of age. 43 of them expired before the age of 3 years, 18 between 3 and 6 
years, and 5 of them were over 6 years old when they died. In two cases no 
age of death was mentioned. From these data the large variation in the 
duration of the disease is also apparent; in 16 children of the infantile group 
the duration of the disease was more than 3 years (figure 1). In the remaining 
18 of 86 children, the first symptoms occurred between 3 and 14 years of age. 
The duration of the disease in this group was less than one year in 6 of the 
children, between 1 and 3 years in another 6, and over 3 years (up to more 
than 10 years) in still another 6 children (figure 1). 
HISTOPATHOLOGIC STUDIES 
CENTRAL NERVOUS SYSTEM 
Macroscopic studies. Macroscopic studies of the central nervous system in 
progressive poliodystrophy showed in general slight or moderate alterations. 
Most conspicuous findings were disseminated foci of cerebral cortical 
atrophy (e.g.19,30,60). Occasionally a slight to severe micrencephaly was 
reported (e.g.34,44,47·52). Frequently dilatation of cerebral ventricles was 
observed (e.g.1117,36). A number of authors mentioned the spongy aspect of 
the cerebral cortex (e.g.60). In several case reports the hippocampal regio was 
explicitly described as normal.1116·23'30·45·46·47·50 
Cerebral white matter showed a fairly normal aspect in most cases reported; 
a firm consistency was mentioned several times (e.g.6). The cerebellum often 
revealed a picture identical to that of the cerebral hemispheres. Abnormali-
ties in brain stem structures and spinal cord were seldom recorded. 
Microscopic studies. The characteristic signs of progressive poliodystrophy 
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are seen on microscopic examination. Most abnormalities are localized in 
cerebral gray matter. In most cases severe neuronal loss was found through­
out the cerebral cortex, together with increase of astrocytes. In many cases 
the neuronal loss was most prominent in the third to fifth cortical layers. In 
several patients loss of the usual cortical cyto-architecture was mentioned 
(most authors mentioned focal or generalized destruction of cortical structu­
res, e.g.1119·45,47). Early changes reported were of a spongy loosening of the 
neuropil with large perineuronal vacuoles and hydropic swelling of the 
astrocytes.30,32 Often dilatation and proliferation of capillaries was described. 
Occasionally neuronal degeneration was observed, with neuronal swelling, 
chromatolysis, and loss of Nissl substance.2,35 In later stages loss of neurons 
with an increase in the number of astrocytes was observed. Finally, a so-
called "spongy state" (status spongiosus) was seen, ensuing from an almost 
complete disappearance of neuronal elements from the residual glial net­
work. 19'29'46 Inflammatory lesions were not reported in any of the descripti­
ons. Inclusion bodies were lacking. 
The above mentioned changes were described as most pronounced in the 
cerebral cortex, they were also common in the cerebellum, thalamus and 
striatum. It was also repeatedly stressed that none or only a few abnormali­
ties were seen in the hippocampus. In the cerebellum there was frequently 
loss of Purkinje cells, and a marked diminution of the granular cell layer, with 
a proliferation of the glia (Golgi astrocytes, Bergmann glia).6,30,32 In some 
cases alterations identical to those in the cortex were observed in the globus 
pallidus and in the brain stem nuclei. Studies of the spinal cord were rarely 
reported; no major abnormalities were indicated.4047 
The cerebral white matter mostly showed no obvious abnormalities. In some 
descriptions a spongy state was recognized in the subcortical and subependy­
mal areas.19,30·44 
Electron microscopic studies. Electron microscopic studies on central nervous 
system tissue from patients with progressive poliodystrophy were reported by 
Suzuki and Rapin50 and by Sandbank and Lerman.45 Suzuki and Rapin50 
described enlarged mitochondria recognizable in the neuronal perikarya and 
axons. Sandbank and Lerman45 found large disorganized perinuclear mito­
chondria in the neurons of cerebral tissue obtained by biopsy. Two types of 
abnormal mitochondria were described in this report. The first type had a 
variable diameter up to 3 μτη and showed very short cristae with intact outer 
and inner membranes. The second type was of normal size and contained 
irregular electron-dense particles within its matrix, adhering to the inner 
membrane or to the cristae. 
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LIVER 
Abnormalities in liver tissue were reported in a relatively large number of 
children with progressive poliodystrophy. Huttenlocher et al26 described four 
patients with a progressive poliodystrophy associated with liver tissue abnor-
malities. They also mentioned four cases recorded earlier by Blackwood et 
al6 and by Wefring and Lamvik.58 Studies of liver tissue in these patients 
showed fairly similar abnormalities: in all the children accumulation of fat in 
parenchymal cells with vacuolation of these cells was observed. Moreover, 
signs of cirrhosis or of subacute hepatitis were seen. In all these cases hepatic 
disease became manifest only late in the course of the disease, and had a 
subacute or chronic rather than an acute course. The clinical and laboratory 
findings in these children were inconsistent with any of the recognized 
illnesses that affect both liver and brain. In all cases the cerebral abnormali-
ties were consistent with progressive poliodystrophy. 
In the cases published after 1976 no abnormalities in liver tissue were 
described, except in the patient reported by Partouche.40 At autopsy steatosis 
was found in this child. It is noteworthy, however, that in this case a liver 
tissue specimen obtained by biopsy at the age of 12 months showed a normal 
aspect. 
SKELETAL MUSCLE 
Histopathologic studies of skeletal muscle tissue were reported only by a few 
authors. Janota29 described abnormalities similar to those seen in a neuroge-
nic muscle atrophy, specifically in the distal muscles of the limbs. An 
extensive histopathologic report of muscle tissue was made by Shapira et al46 
and by Hart et al.23 In both muscle biopsies a "ragged red" appearance of the 
muscle fibers was seen. Electron microscopic studies showed aggregates of 
mitochondria of variable size in the subsarcolemmal areas. Some large 
mitochondria contained paracrystalline bodies. 
The studies of Suzuki and Rapin,50 of Sandbank and Lerman45 and of 
Partouche,40 describing some other children with progressive poliodystrophy 
associated with mitochondrial abnormalities, did not report histopathologic 
studies on muscle tissue. 
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ROENTGENOLOGIC AND ELECTROPHYSIOLOGIC STUDIES 
ROENTGENOLOGIC STUDIES 
The results of cerebral arteriography and of pneumoencephalography are of 
particular relevance to progressive poliodystrophy. These studies were only 
rarely mentioned in the literature. Cerebral arteriography revealed no major 
abnormalities. Central and cortical atrophy demonstrated by pneumoence-
phalography was reported in several studies (e.g.11-34,40,46). Hart et al23 
demonstrated by computed tomography (CT) scanning a cortical atrophy 
with ventricular dilatation in one patient. 
ELECTROPHYSIOLOGIC STUDIES 
Nearly all authors presented electroencephalographic studies. In most cases 
the EEG was abnormal. These abnormalities can be divided in two groups: 
a. In the EEG's of many children slow activity, especially delta waves, was 
present to a greater degree than normal. The pathologic delta-waves were 
diffusely spread,9·25 or with some preferential localization.29·32·58 
b. In the EEG's of many children focal46,50 or generalized irritative activity 
was observed; typical epileptic phenomena were also frequently seen.6,34,46 
The epileptic manifestations had in some cases the aspect of a hyps-
arythmia.26·10·40'46 
Electromyographic and electroneurographic studies were reported in only a 
few cases; no abnormal findings were described. In the literature on progres-
sive poliodystrophy, evoked potentials were not recorded in any of the 
studies. 
BIOCHEMICAL STUDIES 
LABORATORY INVESTIGATIONS 
A survey of the literature on progressive poliodystrophy with respect to the 
routine laboratory investigations revealed no obvious abnormalities. 
Some specific laboratory investigations however are worth mentioning sepa-
32 
rately. Studies on the metabolism of amino acids, organic acids or fatty acids, 
on endocrinopathies, on chronic infectious diseases, on intoxications or on 
vitamin deficiencies showed no consistent abnormalities. In several reports 
liver function tests were abnormal; these deviant values probably reflected 
the histopathologic abnormalities in liver tissue described in the literature.26 
In several cases studies on cerebrospinal fluid (CSF) presented aspecific 
abnormalities, such as a slightly or moderately elevated total protein content 
(up to 5000 mg/1),6·26·29 and in some cases an increased cell count.u·29·32 
STUDIES OF CARBOHYDRATE METABOLISM 
Only five publications mentioned values of lactate and of pyruvate in serum, 
urine and/or in CSF in patients with progressive poliodystrophy, but the 
registered abnormalities were quite remarkable. In general, the levels of 
lactate and pyruvate provide information on the enzymatic processes in 
which pyruvate is converted into C02 and H O by the citric acid cycle and 
respiratory chain (electron transport chain). 
Elevated levels of lactate and pyruvate in serum and/or in CSF were reported 
by Sandbank and Lerman,45 by Shapira et al,46 by Hart et al23 and by 
Partouche.40 Hopkins and Turner25 found normal values of lactate and 
pyruvate in the serum of a patient with progressive poliodystrophy. Suzuki 
and Rapin,50 reporting on morphologically abnormal mitochondria in brain 
tissue, did not mention values of lactate and pyruvate in serum or in CSF. 
Shapira et al46 reported increased levels of lactate and pyruvate in a 24-hour 
urine specimen. 
Partouche40 performed an intravenous lactate load on his patient; this test 
showed an increased rise of lactate and a delayed fall of the lactate levels, 
compared with controls. 
ENZYMATIC STUDIES 
With the exception of Partouche's study,40 no other literature reports men-
tioned enzymatic studies in tissues of patients with progressive poliodystro-
phy. Tommasi et al 51 and Partouche40 reported on a boy with a progressive 
neurologic disorder from his 8,h week of life until his death at 42 weeks. 
Necropsy showed the characteristics of progressive poliodystrophy. Labora-
tory studies revealed normal values of citric acid cycle intermediates in serum 
and of amino acids in urine. Serum levels of lactate and pyruvate however, 
were increased. Enzymatic studies which were performed only on liver tissue, 
obtained at autopsy approximately 20 minutes after death, showed a decrea-
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sed activity of pyruvate carboxylase due to a decreased affinity of the enzyme 
for pyruvate. 
Another study in the literature which is worth mentioning is that of Strömme 
et al,49 reporting a child with a deficiency of the pyruvate dehydrogenase 
complex (PDHC). At autopsy a marked communicating hydrocephalus was 
found with grossly reduced gray and white matter, indicating local but 
extensive destruction of brain tissue. These findings are possibly compatible 
with progressive poliodystrophy. 
DISCUSSION OF LITERATURE DATA 
PROGRESSIVE POLIODYSTROPHY, A NOSOLOGIC ENTITY ? 
There appears to be no unanimity about progressive poliodystrophy and its 
pathogenetic mechanism. The clinical signs which appear in progressive 
poliodystrophy are also seen in other progressive neurologic disorders of 
childhood. The cellular aberrations observed in progressive poliodystrophy 
are also frequently seen after periods of cerebral anoxia. The "Spongy 
Degeneration of the Central Nervous System" (Van Bogaert and Bertrand 
type; Canavan's Disease) is also characterized by a spongy state of the 
cerebral cortex. Van Bogaert, describing the "Spongy Degeneration of the 
Brain" in the Handbook of Clinical Neurology53 referred to "Progressive 
Poliodystrophy" as a rarely occurring special form of the "Spongy Degenera-
tion of the Brain". 
The specific question whether progressive poliodystrophy is due to cerebral 
anoxia or must be regarded as a nosologic entity regularly recurs in discussi-
ons on this disorder. 
In a survey, Alpers3 stated that the presence of the well known pathologic 
features is required as a criterion for correct diagnosis. In the patients 
described by Alpers3 as authentic cases no cerebral anoxia was mentioned in 
the case histories. 
Greenhouse and Neubuerger21 reviewed about forty cases of "degeneration 
of cerebral gray matter" of unknown etiology. They stressed that the variety 
of signs and symptoms makes it impossible to delineate a clear clinical picture 
of the disorder. Moreover, they draw attention to the similarity of pathologic 
features in cerebral anoxia and in the patients described as suffering from 
progressive poliodystrophy. They therefore argued that the disorder may 
well be a response by cerebral gray matter to various noxious influences, and 
that the occurrence of the etiologic factors of the disorder would be extre-
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mely variable. They pointed to cerebral anoxia as the major etiologic factor, 
appearing as a result of perinatal complications, of epileptic manifestations, 
or of other stressful events. In their survey. Greenhouse and Neubuerger 
stated that in the majority of cases a period of cerebral anoxia can be 
demonstrated, and that, if this is not reported, the case history may be 
incomplete. It is therefore their conviction that progressive poliodystrophy is 
always due to cerebral anoxia and that the disorder is not a nosologic entity in 
the true sense. 
A middle course in this discussion was adopted by Jellinger and Seitelber-
ger.30 They agree with Greenhouse and Neubuerger that in a considerable 
number of cases progressive poliodystrophy is the result of various pathologic 
situations, chiefly of cerebral anoxia. These authors argued that in two-third 
of the cases the disease is a symptomatic manifestation; in the history of these 
cases there was sufficient evidence for several etiologic factors, e.g. perinatal 
anoxia, repeated epileptic seizures, or infectious diseases. However, in the 
remaining one-third of the cases they found no principal etiologic factor. 
Jellinger and Seitelberger therefore suggested that these cases are an "idio-
pathic form" of progressive poliodystrophy. Another important argument 
put forward by Jellinger and Seitelberger was that in a number of cases 
several patients were reported within one family. This familial occurrence of 
progressive poliodystrophy suggests that there is a hereditary predisposition, 
as was stressed earlier by Klein and Dichgans.32 Regarding the nature and 
distribution of the abnormalities in cerebral tissue Jellinger and Seitelberger 
proposed that the neuronal degeneration in cerebral gray matter could be 
due to a hereditary metabolic dysfunction. 
The frequently described familial occurrence of progressive poliodystrophy 
lends particular support to Jellinger and Seitelberger's argument that there is 
an "idiopathic form" of progressive poliodystrophy, this disorder being a 
nosologic entity. 
SUMMARY OF LITERATURE DATA 
Progressive poliodystrophy is a neurologic disorder of childhood with an 
autosomal recessive inheritance. The major characteristics are mental retar-
dation or deterioration, epileptic manifestations, myoclonic jerks, and motor 
disability. Visual and auditive dysfunctions were also frequently observed; 
moreover, neurovegetative signs were described several times. In a conside-
rable number of patients the first symptoms appeared in a period of exertion. 
These clinical signs do not point to a specific etiologic factor, but broadly 
indicate a dysfunction of the cerebral gray matter. 
With respect to the age distribution of patients described in the literature a 
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distinction must be made between an infantile and a juvenile form of 
progressive poliodystrophy, as was suggested by Ford.19 In the first group the 
disorder becomes manifest in very early life, the children dying before the 
age of 4 years. In the juvenile form the first symptoms generally occur at the 
age of about 5 years or later; the disease in this group has a less rapidly 
progressive course, the children dying after a variable interval, sometimes in 
adolescence or young adulthood. 
The definite diagnosis of progressive poliodystrophy can only be made by 
microscopic study of brain tissue, at autopsy or in a brain biopsy specimen. 
The disorder is characterized morphologically by degeneration and loss of 
neurons, proliferation of glial elements and dilatation and proliferation of 
capillaries in cerebral gray matter. Similar abnormalities were frequently 
seen in the cerebellum and in the basal nuclei. The cerebral white matter had 
a normal aspect; in some cases hypomyelination was observed. 
Neuroradiologic investigations revealed uncharacteristic pictures. Electroen-
cephalographic studies frequently showed a disturbed cerebral function. Two 
different features were reported from the EEG: diffuse slowing (delta waves) 
of the background rhythm, and focal or generalized irritative or epileptic 
activity. It might be expected that evoked potentials (particularly the cortical 
responses) would also be disturbed; however, in the literature on progressive 
poliodystrophy there was no report of evoked potentials. 
Routine laboratory studies and studies on inborn errors of metabolism 
showed no remarkable abnormalities. In some patients abnormal liver func-
tion tests were seen. 
In several patients specific studies of lactate and pyruvate were performed in 
serum and in CSF. In most of these cases increased levels of lactate and 
pyruvate were measured. 
Microscopic studies of liver tissue revealed slight to moderate signs of 
parenchymal fatty degeneration. However, there is no other resemblance to 
Reye's syndrome, a hepatocerebral degeneration with much more severe 
abnormalities in liver tissue.4,42 
Histochemical and submicroscopic studies of skeletal muscle tissue in 
patients with progressive poliodystrophy showed abnormalities in mitochon-
dria in several cases. 
The findings of elevated levels of lactate and pyruvate in serum and in CSF 
on the one hand, and the morphologic abnormalities in muscle tissue 
mitochondria and incidentally in neuronal mitochondria on the other, may 
point to a defect in the intramitochondrial pyruvate metabolism. In the 
literature such a possibility was suggested by Shapira et al46 and by Hart et 
al.23 Partouche40 presented a patient with progressive poliodystrophy in 
combination with a pyruvate carboxylase deficiency in liver tissue obtained at 
autopsy. 
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These findings may indicate that the association of progressive polio-
dystrophy and a defective pyruvate metabolism is more than a mere coinci-
dence. Therefore, when searching for pathogenetic factors in progressive 
poliodystrophy it seems worthwhile to direct attention to abnormalities in 
pyruvate metabolism. In chapter 2 a summary of cerebral carbohydrate 
metabolism will be presented together with an introduction to our studies. 
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CHAPTER 2 
MAIN CHARACTERISTICS OF THE CEREBRAL 
CARBOHYDRATE METABOLISM 

INTRODUCTION 
In chapter 1 it was concluded that it would be worthwhile investigating 
pyruvate metabolism in children suspected of progressive poliodystrophy. 
Chapter 2 will present an outline of the cerebral carbohydrate metabolism 
and a survey of neurologic disorders associated with disturbances of pyruvate 
metabolism. In conclusion, chapters 3-6 will be introduced in a short para-
graph; in these chapters our patient studies will be presented. 
The carbohydrate metabolism is particularly important for a properly functi-
oning central nervous system. Under normal conditions, the quantitatively 
most important substrate of cerebral energy metabolism is glucose. A 
transient decline in the oxidative metabolism of glucose may lead to an 
abrupt disruption of brain function. 
When glucose falls below need, primarily glycogen is degraded to glucose in 
glycogenolysis; thus glycogen acts as a carbohydrate reserve. Glucose can 
also be formed in gluconeogenesis. Glycogenolysis and gluconeogenesis do 
not occur in brain tissue. Substrates for cerebral energy metabolism in 
circumstances of glucose-shortage are the ketone bodies (ß-hydroxybutyrate 
and acetoacetate). It is possible that lactate can also be used as a substrate in 
cerebral energy metabolism.1015·28,33 
SOME BIOCHEMICAL ASPECTS OF CARBOHYDRATE METABOLISM 
Pyruvate has a central position in carbohydrate metabolism. Carbohydrate 
metabolism can be divided into a number of main pathways: glycogen 
synthesis and glycogenolysis, glycolysis (Embden-Meyerhof pathway) and 
gluconeogenesis. Figure 1 gives a general survey of the main metabolic 
pathways of carbohydrate metabolism. 
The main site of glycogen synthesis and glycogenolysis is the liver. Gluconeo-
genesis occurs predominantly in the liver and the kidney. Glycolysis is the 
only pathway of carbohydrate metabolism occurring in brain. In this pathway 
a molecule of glucose is broken down into two molecules of pyruvate or 
lactate. 
In the citric acid cycle (Krebs cycle) acetyl-CoA, derived from pyruvate, fatty 
acids or amino acids, as well as citric acid cycle intermediates derived from 
amino acids, can be oxidized to C0 2 (figure 2). Reducing equivalents are 
made available for ATP synthesis in the electron transport chain (respiratory 
chain) (figure 3). 
Pyruvate oxidation occurs in the mitochondria via the pyruvate dehydroge-
nase complex. The acetyl-CoA formed is further oxidized in the citric acid 
cycle and the respiratory chain. 
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= lactate 
acetyl CoA —" ^. ketone bodies 
Figure 1. The main metabolic pathways of carbohydrate metabolism. 
Two important intramitochondrial enzyme systems in pyruvate metabolism 
are the pyruvate dehydrogenase complex (PDHC) and pyruvate carboxylase 
(PC). PDHC catalyzes in the presence of lipoic acid, thiamine pyrophosphate 
(TPP) and Mg2+ the reaction: 
pyruvate + CoA + NAD+ -• acetyl-CoA + C0 2 + NADH + H
+ 
According to Blass9 this reaction is normally the rate-limiting step for entry 
of pyruvate from glycolysis into the Krebs cycle. The PDHC consists of three 
catalytic enzymes: pyruvate dehydrogenase (E ), dihydrolipoate transacety-
lase (E2) and dihydrolipoate dehydrogenase (E3), and of two regulating 
enzymes: pyruvate dehydrogenate phosphatase and pyruvate dehydrogenate 
kinase. 
Pyruvate carboxylase is a biotin-dependent enzyme, catalyzing the reaction: 
pyruvate + CO + ATP + H O -> oxaloacetate + ADP + Ρ 
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NADH + H"1"-
NAD + 
Figure 2. CKrlc acid cycle. 
2-Oxoglirtarate -*-' 
According to Blass9 this reaction is probably the rate-limiting step in glucone-
ogenesis. 
The PDHC and PC are of great importance in directing the pyruvate flow. In 
general, metabolic conditions which stimulate pyruvate carboxylation (e.g. 
oxidation of fatty acids) inhibit the oxidation of pyruvate. Disturbances in 
citric acid cycle activity may result in a decrease of the pyruvate oxidation 
rate, due to increase of the acetyl-CoA/CoA ratio, which inhibits the PDHC. 
Likewise, disturbances in the electron transport chain may impair or decrease 
pyruvate oxidation rate or citric acid cycle activity by feedback inhibition due 
to an increased NADH/NAD+ ratio.9-33 
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Figure 3. Electron transport chain. 
As mentioned above, under normal conditions glucose is an almost indispen­
sable substance for good brain function. Abnormalities of carbohydrate 
metabolism can reasonably be expected to impair the function of the central 
nervous system.5 
PYRUVATE METABOLISM AND NEUROLOGIC DISORDERS 
Several defects in pyruvate metabolism were reported in association with 
neurologic disorders. The most frequently reported defects are those of the 
pyruvate dehydrogenase complex (e.g.3 , 8 1 4 , 2 1), of pyruvate carboxylase 
(e.g.1·1119·24) and of the cytochromes ^^льжтз^зизіу 
In the literature disturbances of the pyruvate metabolism were reported in 
several neurologic disorders with autosomal recessive inheritance. The first 
description of a neurologic disease associated with a defective pyruvate 
metabolism was the report of a 9-year-old boy with intermittent ataxia, 
occurring after nonspecific febrile illnesses;3,4 a deficiency of pyruvate decar­
boxylase was demonstrated in muscle tissue. Since this report disturbances of 
pyruvate metabolism have been described in patients with various neurologic 
disorders, especially Subacute Necrotizing Encephalomyelopathy (Leigh syn­
drome) (e.g.6 1 2 1 4·2 2) and Friedreich's ataxia (e.g.2,7·20). Disturbances of 
pyruvate metabolism have also been demonstrated in hereditary motor and 
sensory neuropathy (HMNS type I, Charcot-Marie-Tooth disease),34 in spi­
nocerebellar degeneration21 and in a progressive neurologic disorder charac-
Succmate 
FAD 
IN »-Q — > - c y t b — » - c y t c + c ¡ — » - c y t а а з — > - O2 
^ s 
Г 
ADP + Pi 
ATP 
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Table 1. Biochemical and morphologic findings Indicating a defective energy metabo-
lism, as reported In the literature In five children with progressive pollodystrophy. 
Case no' 
Biochemical studies 
Lactate 
Pyruvate 
Ratio UP 
Morphologic 
Muscle 
Liver 
Brain 
serum 
CSF 
serum 
CSF 
serum 
CSF 
studies 
64 
-
_ 
-
; 
giant neuronal 
mitochondria 
69 
Î 
N 
Î 
; 
giant neuronal 
mitochondria 
78 
î 
î 
î 
Ν 
î 
î 
mitochondrial 
myopathy 
~ 
83 
î 
î 
î 
lipid storage 
— 
86 
î 
î 
Ν 
Ν 
î 
î 
mitochondrial 
myopathy 
-
* Cases are numbered as in chapter 1, table 1 
- = not mentioned 
terized by diffuse hypomyelination.1,26 Thus, disturbances of pyruvate meta-
bolism have been demonstrated in several so-called degenerative neurologic 
disorders, with pathologic abnormalities in various neuronal systems with 
various localizations in the nervous system. 
In chapter 1 several patients with progressive poliodystrophy were mentio-
ned, in whom biochemical or morphologic studies pointed to a disturbed 
carbohydrate metabolism.'^24·25·27·30 Table 1 summarizes these cases in the 
literature. Partouche24 reported a child with progressive poliodystrophy and 
a defect in pyruvate carboxylase activity in liver tissue. This study will be 
limited to disturbances in pyruvate metabolism in progressive poliodystrophy 
(Alpers' disease). 
INTRODUCTION TO OUR STUDIES 
From the literature data one may expect a disturbance in the carbohydrate 
metabolism in patients with progressive poliodystrophy.1724·25,27 Extensive 
metabolic studies were therefore carried out on children suspected of this 
disorder. Chapters 3-6 contain the case reports of five children with progres-
sive poliodystrophy. Detailed clinical, pathologic and biochemical investiga-
tions, performed on these children, are described in these chapters. Chapter 
7 summarizes these data, and gives some correlations with the literature 
studies in chapters 1 and 2. 
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The pathologic and biochemical findings are discussed in chapter 3-6 in 
relation to the individual case reports, and in a general discussion in chapter 
7. Further, some conclusions are formulated in chapter 7, and some suggesti­
ons for further investigations are made. 
чп 
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CHAPTER 3 
PYRUVATE DEHYDROGENASE 
DEFICIENCY RESTRICTED TO BRAIN 
M Prick, F Gabreëls, W Renier, F Trijbels, H Jaspar, 
К Lamers and J Kok 
Neurology (Ny) 31:398-404, 1981 
ABSTRACT 
We studied a child with a rapidly progressive neurologic disorder, with 
psychomotor retardation, hypotonia, seizures, and respiratory disturbances. 
Laboratory studies showed elevated levels of lactate and pyruvate in cere-
brospinal fluid (CSF), without notable elevated levels in serum. In liver, 
muscle, leukocytes, and cultured fibroblasts we found no abnormality in 
pyruvate oxidation; biochemical studies of a brain biopsy showed an isolated 
deficiency of pyruvate dehydrogenase complex in brain tissue with the 
morphologic picture of progressive poliodystrophy with hypomyelination. 
INTRODUCTION 
The first description of a deficiency in the pyruvate dehydrogenase complex 
(PDHC) was published 10 years ago by Blass et al1,2, and other cases were 
described later3"16. Blass17 has reviewed the different clinical disorders associ-
ated with abnormal pyruvate metabolism (especially deficiencies of pyruvate 
carboxylase and the pyruvate dehydrogenase complex). If PDHC activity is 
less than 15% of normal, neurologic disorder is severe in early childhood, and 
characterized by severe psychomotor retardation, spasticity, hypotonia, 
ataxia, visual disturbances, lactate acidosis, and seizures. If PDHC activity is 
20 to 35% of normal, the disease is less severe with the same symptoms, but 
manifests later and is more slowly progressive. Ataxia is often the most 
prominent symptom. A mild disease may be seen with enzymatic activity of 
35 to 50% of normal; hereditary ataxias dominate this category. 
We now describe an infant with PDHC deficiency in brain, but not in other 
tissues. 
CASE REPORT 
This girl was the first child of healthy, nonconsanguineous parents. Preg-
nancy was normal and delivery occurred without complications at term. The 
birth weight was 3000 gm; the Apgar score was 9 after 1 minute. In the first 2 
weeks of life there was no overt abnormality. In the second month, she 
became hypotonic, with intermittent myoclonic contractions and nystagmoid 
ocular movements. At 8 months, she was admitted to the hospital for 
myoclonus status with slight fever and Cheyne-Stokes respiration. At 18 
months, she was admitted to our department. 
There was severe psychomotor retardaton with microcephaly, and she did 
not yet walk or talk. Length and weight were normal. Cheyne-Stokes 
respiration was frequently seen. Absences, tonic-clonic seizures, and genera-
lized myoclonic contractions occurred often (in periods several times a day). 
She was extremely hypotonic and showed severe limb ataxia. Tendon 
reflexes were present and plantar responses were extensor. There were 
nystagmoid ocular movements; visual fixation did not seem possible. Fundo-
scopy was normal. She seemed to hear, and sensation appeared to be intact. 
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ELECTROPHYSIOLOGIC AND RADIOLOGIC INVESTIGATIONS 
Radiograms of chest, skull, and hands were normal. The electroencephalo­
gram (EEG) showed mild generalized slowing with no epileptic pattern. 
Electromyography and nerve conduction velocities were normal. Somatosen­
sory potentials could not be elicited. Carotid and vertebral artery angio­
graphy were normal. Pneumoencephalography showed symmetric and slight 
enlargement of the lateral ventricles, with normal third and fourth ventricles. 
Computed tomography (CT) scanning was not performed. 
ROUTINE AND SPECIFIC LABORATORY INVESTIGATIONS 
Standard blood and urinary studies, including hematologic evaluation, renal 
and hepatic functions, serum protein, and serum protein electrophoresis were 
normal. Appropriate studies excluded mercury and lead intoxication; defi­
ciencies of thiamine, pyridoxine, cobalamine, folate, and ascorbate; abnor­
malities of Τ , T4, cortisone-rhythm, calcium, phosphorus, and oral glucose 
tolerance; and tuberculosis, toxoplasmosis, or syphilis. 
Other normal studies included arterial blood pH, serum lipids, amino acids in 
plasma and urine, plasma short-chain fatty acids and organic acids, lysosomal 
enzymes, creatine Phosphokinase, ammonia, magnesium, serum copper, 
ceruloplasmin, fructose, and galactose. Serum levels of lactate and pyruvate 
were in the upper-normal range or were slightly elevated (normal = 600 to 
1200 μπιοί per liter and 75 to 120 μπιοί per liter, respectively; elevated = 800 
to 1350 μπιοί per liter and 100 to 130 μπιοί per liter, respectively); 24-hour 
urinary excretion of lactate and alanine was normal. 
Cerebrospinal fluid (CSF) cell count, protein content, protein electrophoresis 
and immune-electrophoresis, minerals, acetoacetate, and ß-hydroxybutyrate 
were normal. Lactate and pyruvate levels in CSF were elevated proportio-
nally several times (table 1). Therefore, the laboratory data showed an 
isolated increase of lactate and pyruvate in CSF with a normal ratio. 
Suspecting a primary defect in pyruvate metabolism (figure 1), we had to 
Table 1. Glucose, lactate, and pyruvate levels In cerebrospinal fluid (CSF) of patient 
and controls. 
Patient 
Controls 
Glucose 
(μπιοΐ/ΐ) 
3.5-3.7 
3.5-1.5 
Lactate 
(цтоі/і) 
2500-3000 
1200-1600 
Pyruvate 
(цтоі/і) 
191-204 
90-130 
Ratio 
Lactate/Pyruvate 
13.1-14.7 
11.0-14.5 
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Figure 1. Cerebral oxidative metabolism. 
distinguish between deficiencies of oxidation and carboxylation, and between 
the quantitatively severe and milder defects. 
Ή55υΕ STUDIES 
HISTOCHEMICAL AND ULTRASTRUCTURAL STUDIES 
Histochemical and ultrastructural studies were performed on liver and mus­
cle, both obtained by biopsy. No morphologic abnormalities were found. 
BIOCHEMICAL STUDIES IN TISSUES 
Enzymatic studies were performed in liver and muscle homogenates, whole 
white blood cells, and intact cultured fibroblasts. Pyruvate oxidation rate and 
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Table 2. 1 4 C 0 2 production from [1-"C] pyruvate (PDHC activity) and from [2-1 4C] 
pyruvate (activity of the citric acid cycle) In cultured fibroblasts, In leukocytes and In 
liver tissue of patient and controls. 
Fibroblasts 
Leukocytes 
Liver tissue 
Substrate 
[1-14C] pyruvate 
[2-'4C] pyruvate 
[1-"C] pyruvate 
[2-14C] pyruvate 
[l-^C] pyruvate 
Patient 
66 7* 
210 
6 0* 
44 
42 0* 
Controls 
41 0 ± 14 
20 7 ± 7 
28 ± 12 
24 ± 1.0 
45 -205 
(n=22) 
(n=14) 
(n=17) 
(n=14) 
(n= 9) 
• nmol/hr/mg protein 
+ nmol/hr/lO6 leukocytes 
citric acid cycle activity were evaluated in intact fibroblasts and leukocytes by 
measuring 14C02-production from [l-14C]pyruvate and [2-14C]pyruvate, res­
pectively, using a modification of the method of Blass et al1 (see Willems18). 
Pyruvate oxidation rate in a liver tissue homogenate was studied by measu­
ring 14C02-production from [l-'^Jpyruvate.118 Pyruvate carboxylase activity 
was assayed in the same liver homogenate by the method of Utter et al19. 
Cytochrome с oxidase activity was measured in liver and muscle homoge­
nate.1820 
Pyruvate oxidation rate and citric acid cycle activity were normal in leukocy­
tes and cultured fibroblasts. In liver, pyruvate oxidation rate was slightly 
decreased, but within normal limits (table 2). Pyruvate carboxylase activity in 
liver was normal. Cytochrome с oxidase activity was normal in liver and 
muscle. 
CEREBRAL BIOPSY 
The biopsy was taken from the second convolution of the right frontal lobe. 
The specimen for biochemical studies was preserved in ice, and biochemical 
analysis was started immediately. 
MORPHOLOGIC STUDIES 
Microscopic, histochemical, and ultrastructural studies were performed in 
brain tissue. 
In gray matter, microscopy showed foci of local degeneration and loss of 
neurons, most pronounced in the deeper cortical layers. Neurons showed loss 
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Figure 2. Horseshoe-shaped area around the base of a sulcus with degeneration and 
loss of neurons, with maximal intensity in the deeper parts of the gray matter. There Is a 
sharp limit where gray matter passes Into white matter. Hematoxylin and eosin, χ 55. 
• · • Ψ, 
Figure 3. Vascular proliferation and reactive activity of astroglia and microglia In the 
area with degeneration and loss of neurons. Hematoxylin and eosin, χ 550. 
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Table 3. 14C02 production (nmol/hr/mg protein) from [1-14C] pyruvate In brain tissue, 
without malate (PDHC activity) and with malate (activity of the citric acid cycle), In our 
patient and eleven other patients undergoing a cerebral biopsy. 
Age [ l - ' t ] pyruvate [1-MC] pyravate + malate 
(yrs, mos) Gray matter White matter Gray matter White matter 
Patient 
J J 
J P 
M S 
M P 
A D 
W A 
W L 
G G 
E R 
G Q 
M H 
Mean 
values 
16 
14 
15 
1 5 
1 8 
19 
2 0 
2 3 
5 6 
6 11 
10 9 
15 9 
7 
144 
75 
120 
201 
188 
153 
42 
54 
133 
110 
220 
131 ± 59 
(n=l l ) 
6 
126 
68 
68 
103 
174 
118 
30 
31 
63 
46 
54 
80 ± 45 
(n= l l ) 
12 
536 
85 
387 
725 
517 
415 
131 
-
468 
285 
568 
412 ± 199 
(n=10) 
7 
502 
86 
151 
-
454 
297 
86 
-
206 
126 
156 
229 ± 155 
(n=9) 
of tigroid substance, microvacuolization, and some lipid storage. There was a 
proliferation of astroglia, microglia, and blood vessels. In white matter, 
myelin and axons appeared qualitatively intact, although there were signs of 
hypomyelination. No active demyelination was seen. The process was classi-
fied as progressive infantile poliodystrophy (Alpers disease), associated with 
hypomyelination (figures 2 and 3). 
BIOCHEMICAL STUDIES 
Pyruvate oxidation in brain was measured in a homogenate by measuring 
14CO production, as above.11814CO production was measured with and 
without malate. Stimulating 14CO production from [l-14C]pyruvate with 
malate raises the activity of the citric acid cycle, but has no effect if PDHC-
activity is impaired. Cerebral ketooxidation was measured by measuring the 
ß-hydroxybutyrate production. Cytochrome с oxidase activity was measured 
in gray and white matter, as before.1 8 2 0 
1 4CO production from [1-14C] pyruvate with or without malate was severely 
decreased in both gray and white matter (table 3). Cerebral ketooxidation 
and cytochrome с oxidase activity were normal in both gray and white 
matter; the controls were children undergoing a cerebral biopsy with several 
neurologic disorders, as severe progressive oligophrenia, infantile Batten 
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Table 4. Effect of therapy with ketonemlc diet, thiamine, llpolc acid, and aspartic acid on 
lactate and pyruvate In cerebrospinal fluid (CSF) of patient. 
Without therapy 
Ketonemic diet 
Thiamine 1200 mg per day 
Lipoic acid 120 mg per day 
Aspartic acid 3000 mg per day 
Controls 
2500-3000 
2480 
2600 
3060 
1200-1600 
Lactate Pyruvate 
Therapy (цтоі/і) (цтоі/і) 
191-204 
160 
164 
180 
90-130 
disease, angiomatosis meningae, leukoencephalitis, Canavan disease, and 
Pelizaeus-Merzbacher disease. 
EFFECTS OF THERAPY 
First we used a ketogenic diet,8 followed by lipoic acid (40 mg three times 
daily) in combination with thiamine (300 mg three times daily),21"24 Finally, 
aspartic acid (1000 mg three times daily) was given, but there was no clinical 
or biochemical improvement (table 4). 
Six months later, she suddenly became comatose and died; no permission was 
given for autopsy. 
DISCUSSION 
This 16-month-old infant suffered from a rapidly progressive disorder mani­
fested by psychomotor retardation, microcephaly, hypotonia, respiratory 
disturbances, epileptic seizures, abnormal ocular movements, ataxia, and 
extensor plantar responses. Somatosensory evoked potential studies gave no 
response at all. Pneumoencephalography showed slight central cerebral 
atrophy. CSF lactate and pyruvate levels were increased, but there were only 
slightly increased levels of lactate and pyruvate in serum and urinary excre­
tion of lactate, and alanine was normal. Acquired disorders of pyruvate 
metabolism with impaired cerebral oxidative metabolism (e.g., infections 
and vascular disorders) were excluded (normal angiograms and CSF values). 
Pyruvate oxidation and the activity of the citric acid cycle were normal in 
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Table 5. Previously reported patients with PDHC deficiency 
Group I 
Severe disease 
(10 patients) 
First symptoms 
in early infancy 
(0-6 months) 
Rapidly progressive 
Severe mental retardation 
Microcephaly 
Ataxia 
Hypotonia 
Spasticity 
Optic atrophy 
Seizures 
Respiratory distress 
Lactic acidosis 
serum 
lactate » 9/9 
pyruvate «• 7/7 
alanine » 5/5 
PDHC deficiency 
demonstrated in·* 
cultured fibroblasts 
leukocytes 
liver tissue 
Autopsy 
poliodystrophy 1 
hypomyelination 2 
leigh's syndrome 1 
CSF 
— 
1/1 
Group II 
Less severe disease 
(7 patients) 
in early childhood 
(0-2 years) 
Slightly progressive 
Mental retardation 
Microcephaly 
Ataxia 
Hypotonia 
Spasticity 
Optic atrophy 
Seizures 
Respiratory distress 
serum CSF 
7/7 2/2 
6/6 2/2 
2/2 1/1 
cultured fibroblasts 
leukocytes 
liver tissue 
Group HI 
Mild disease 
(syndromes of spinocerebellar ataxia) 
variable 
(5-15 years) 
Slowly progressive 
Ataxia 
in some cases 
elevated 
in serum 
cultured fibroblasts 
leukocytes 
•Group I 
Group II 
Group III 
Cultured fibroblasts (seven patients), cultured fibroblasts and leukocytes (one patient), in one 
patient PDHC activity was decreased in liver tissue, but normal in cultured fibroblasts and 
leukocytes 
Cultured fibroblasts (six patients), cultured fibroblasts and liver tissue (one patient) 
Cultured fibroblasts in most cases, leukocytes in some cases, too 
cultured fibroblasts and in leukocytes. In the liver, pyruvate oxidation was in 
the lower range of normality. In the brain, ketooxidation and cytochrome с 
oxidase activity were normal, but 1 4C0 2 production from [1-14C] pyruvate 
(with or without malate) was severely decreased in both gray and white 
matter, suggesting lack of PDHC activity only in cerebral tissue, which is a 
pattern not previously described. Blass states that there is little evidence of 
isoenzymes of PDHC.25 Therefore, the activity of PDHC in tissues easily 
obtained by biopsy (such as fibroblasts) should reflect PDHC activity in the 
brain. However, our case demonstrates a selective decrease of PDHC activity 
in the brain. 
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As in other tissues, hypoxia increases lactate production and concentration in 
brain. When a steady state exists, there is a diffusion equilibrium between 
CSF and cerebral tissue fluids.26 Elevated lactate concentration in CSF with 
almost normal serum lactate content was also consistent with altered mito-
chondrial function in brain. It is uncertain if this abnormality in brain was the 
primary enzymatic deficiency or secondary to some other disorder. 
Table 5 reviews patients with a proven PDHC deficiency with their main 
clinical, biochemical, and pathologic features. In general, a deficiency in the 
PDHC is demonstrated in cultured fibroblasts and/or in liver tissue, someti-
mes in leukocytes. The clinical, biochemical, and pathologic abnormalities of 
the previously described case conform to the "severe" category of PDHC 
deficiency. Blass17 suggested that there is only one biochemical characteristic 
in these disorders: increased levels of lactate and pyruvate in blood and 
increased levels of alanine in blood and urine. In our patient, lactate and 
pyruvate levels were normal in blood, but increased in CSF. In similar 
diseases, CSF levels of lactate and pyruvate should be studied and included in 
future classification. The clinical signs in our case were similar to others 
attributed to deficiency of PDHC,1'16 thiamine,21"24 the respiratory chain,17 or 
pyruvate carboxylase,27 which all concern pyruvate metabolism. At autopsy, 
several pathologic entities can cause similar symptoms, including subacute 
necrotizing encephalomyelopathy (Leigh disease),6,9·12·22· ^· ** progressive 
infantile poliodystrophy (Alpers disease),30,31 or extensive hypomyelination.7 
Pincus stressed respiratory symptoms as a key manifestation of Leigh dis-
ease,22 occurring in 75% of the patients. 
Respiratory abnormalities include dyspnea, tachypnea, and apnea - all signs 
of a brainstem disorder. Our patient had many respiratory problems and died 
because of respiratory insufficiency. Autopsy was not permitted, so we do 
not know the pathology in the brainstem. However, there was a poliodys-
trophy with hypomyelination in the cortical biopsy. 
Therefore, a severe disturbance of the cerebral PDHC may be associated 
with several pathologic disorders, including subacute necrotizing encephalo-
myelopathy (Leigh disease), progressive infantile poliodystrophy (Alpers 
disease), and hypomyelination. Milder disorder of the cerebral PDHC may 
give rise to syndromes of spinocerebellar ataxia. 
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CHAPTER 4 
PROGRESSIVE INFANTILE POLIODYSTROPHY 
ASSOCIATION WITH DISTURBED PYRUVATE OXIDATION 
IN MUSCLE AND LIVER 
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ABSTRACT 
Progressive infantile poliodystrophy (Aipers' disease) is associated with 
abnormalities in pyruvate metabolism or in cell mitochondria. A 3-year-old 
boy had a severe and rapidly progressive neurologic disorder characterized 
by psychomotor retardation, tetraparesis, ataxia, and myoclonic jerks, the 
illness being exacerbated during periods of infection. Lactate concentration 
in CSF was elevated. Histopathologic studies revealed lipid storage in liver 
and muscle. Autopsy showed a progressive infantile poliodystrophy. Mito­
chondrial abnormalities were found in heart muscle. Biochemical studies of 
muscle and liver tissue suggested a disturbance in nicotinamide adenine 
dinucleotide (reduced form) oxidation. 
Ύ> 
INTRODUCTION 
Since the description of a mitochondrial myopathy by Luft et al,1 many 
patients have been described as having structural or biochemical abnormali­
ties in muscle mitochondria. Recently, Di Mauro et al2 have stated that the 
definition of mitochondrial myopathies by morphologic or clinical criteria 
alone is inadequate. In their opinion, a rational classification should depend 
on the identification of the various biochemical abnormalities. 
The combination of progressive infantile poliodystrophy (Alpers' disease) 
and a mitochondrial myopathy has been described by Shapira et al3 and Hart 
et al,4 but a biochemical defect was not identified in these cases. Tommasi et 
al5 and David et al6 reported a case of progressive infantile poliodystrophy in 
association with a deficiency of pyruvate carboxylase in liver. 
We describe a patient with progressive infantile poliodystrophy, in whom 
pyruvate oxidation in muscle and liver was disturbed; a thorough biochemical 
and morphologic study of this case was possible. 
REPORT OF A CASE 
A boy, the first child of healthy, nonconsanguineous parents, was born after 
an uneventful pregnancy and delivery; birth weight was 2,750 g; the newborn 
child showed no abnormalities. There was slightly retarded motor and speech 
development. He became fatigued rapidly, and during infectious diseases 
ataxic gait was evident. 
Examination at the age of DA years revealed a slight psychomotor retarda­
tion, a severe spastic paresis, and signs of ataxia. From the age of 3 years, 
febrile periods, sometimes with loss of consciousness, were increasingly 
frequent. Myoclonic contractions developed, and the boy's general condition 
gradually deteriorated. When З'/г years old, he was admitted to our depart­
ment, following further deterioration of his condition. 
The boy was quite pale, with extensive edema, most pronounced in face and 
neck. Head circumference (52 cm), height, and weight were normal. There 
were no cardiac or pulmonary abnormalities. He showed general hypotonia, 
tetraparesis, and hyperreflexia with extensor plantar responses. Mainly in the 
right arm and leg, myoclonic contractions were almost continuous. He failed 
to react to pain stimuli. Disturbances of ocular movements were not ob­
served. 
The child remained in a rather stable condition for about six weeks, with 
changing grades of consciousness, intermittent respiratory disturbances, and 
myoclonic contractions. Biopsies of liver, sural nerve, and soleus muscle were 
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performed in this period. Then hepatic insufficiency set in, attended by 
oliguria, jaundice, and Cheyne-Stokes respiration. His condition grew worse 
and he died, 3 years and 9 months old. 
RADIOLOGIC AND ELECTROPHYSIOLOGIC EXAMINATIONS 
Roentgenograms of chest, skull, and hands were normal. On cerebral compu­
ted tomography, the lateral ventricles were enlarged, whereas the fourth 
ventricle was normal. The EEG showed severe generalized slowing, with 
signs of dysfunction of the deep structures, and sometimes paroxysms with 
epileptic features. Somatosensory envoked potentials could not be elicited. 
Nerve conduction velocities and electromyograms were normal. 
LABORATORY DATA 
The following laboratory tests and data were normal: complete blood cell 
count and urinalysis, renal and hepatic function tests, serum electrolyte 
levels, serum protein content and electrophoretic pattern, serum lipid spec­
trum, serum pH, Pco and bicarbonate, creatine kinase, ceruloplasmin, amino 
acid levels in plasma and urine, short-chain fatty acid and organic acid levels 
in urine, and lysosomal enzyme levels in leukocytes. Appropriate studies 
ruled out endocrinologie, immunologic, and chronic infectious diseases, 
deficiencies, and disorders caused by toxic agents. 
Serum lactate and pyruvate levels were within normal ranges; 24-hour lactate 
excretion in urine was normal. The oral glucose tolerance test revealed a 
normal response of blood glucose with elevated levels of lactate (4,170 
цто1е/Ь; normal < 1,500 μπιο\ε/ν) and pyruvate (200 цто1е/Ь; normal < 
95 цто1е/Ь), both at 60 minutes, with a high lactate-pyruvate ratio (21; 
normal, 6 to 10). Studies on CSF showed normal WBC count, normal protein 
electrophoresis and Immunoelectrophoresis, and normal concentrations of 
ketone bodies, but elevated total protein content (560 mg/L), lactate dehy­
drogenase level (75 units/L; normal, 10 to 25 units/L), and SGOT level (20 
units/L; normal, 4 to 10 units/L). The CSF glucose and pyruvate levels were 
within normal ranges, but the level of lactate was elevated, ranging from 
2,080 to 2,840 μϊηο\ε^ (normal, 1,200 to 1,600 μιτιοΜΙ.), with an increased 
lactate-pyruvate ratio (19 to 23; normal, 11 to 15). 
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HISTOPATHOLOGIC STUDIES 
Necropsy disclosed cirrhosis and severe steatosis of the liver, congested 
kidneys, and signs of a subendocardial myocardial infarction. Specimens of 
skeletal muscle, peripheral nerve, and liver, obtained at biopsy, were availa­
ble for histochemical and electron microscopic studies. Heart muscle and 
CNS tissue, obtained 12 hours post mortem, were studied by light and 
electron microscopy. 
SKELETAL MUSCLE 
Histochemical studies of the soleus muscle showed a decrease of type I fibers 
(47%; normal, 65%); Sudan black-positive droplets were seen, particularly in 
type I fibers (figure 1). In the trichromic-stained section, no ragged red fibers 
were seen. The nicotinamide adenine dinucleotide, reduced form (NADH) 
tetrazolium reductase reaction and the menadione-linked α-glycerol phos­
phate dehydrogenase reaction were qualitatively normal. Electron micro­
scopy revealed a slight increase of lipid vacuoles among the myofibrils. 
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Figure 2. Electron micrograph showing part of heart muscle fibers. Note numerous 
ilpid droplets, either eiectrodense or electroiucent (arrows). Most mitochondria have 
irregular, swollen crlstae; η Indicates nucleus (x 12,400). 
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Figure 3. Electron micrograph, with three liver cells partly visible. Fair amount of 
smooth endopiasmatic reticulum with irregular branching aspect of lamellae (arrows); m 
indicates mitochondria (x 27,900). 
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HEART MUSCLE 
Light microscopy showed an increase of collagen fibers without inflammatory 
infiltrate, suggesting interstitial fibrosis. Electron microscopy revealed a 
diffuse deposition of large and small lipid droplets in nearly all muscle fibers, 
both perinuclear and among the myofibrils. The cristae of the mitochondria 
did not have a tubular structure but a widened and often vesicular aspect 
(figure 2). 
LIVER 
Electron microscopy disclosed many intracytoplasmatic lipid droplets. The 
mitochondria showed an abnormal variation in shape and size. There was 
also an increase of smooth endoplasmic reticulum with an irregular ramifying 
lamellar network (figure 3). 
PERIPHERAL NERVE 
Light and electron microscopy of sural nerve tissue showed slight signs of 
active primary axonal degeneration (Wallerian degeneration). 
CNS 
External examination of the brain presented a slight atrophy of the cerebral 
hemispheres and a moderate atrophy of the cerebellar hemispheres. The 
frontal cortex appeared thinner and darker than usual. In several areas the 
cortex split easily, and on close inspection a rim of vacuoles could be seen in 
the middle layers of the cortex. The ventricles were enlarged. 
On light microscopic examination, the most striking changes were a spongio-
sis of the cortical layers together with pericellular and perivascular edema. 
There was marked degeneration and loss of cortical neurons, together with 
considerable proliferation of astrocytes. No inflammatory signs or intranu-
clear inclusion bodies were seen. Cortical changes varied in different regions. 
Some parts of the cortex were normal or nearly so. The white matter 
presented a normal myelin structure; the Oligodendroglia! cells were normal 
in number and appearance. In the cerebellar cortex we found an extensive 
loss of Purkinje's cells and of neurons of the granular layer, as well as a slight 
proliferation of Bergmann's glia. There was also degeneration and loss of 
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neurons in the basal ganglia, pons, dentate nucleus, and inferior olive; a 
lumbar spinal ganglion showed extensive loss of neurons. 
Electron microscopy of the cerebral cortex revealed extensive postmortem 
autolytic changes. No major mitochondrial abnormalities (eg, giant mito-
chondria) were seen in neurons or astroglia. 
BIOCHEMICAL STUDIES 
MATERIALS AND METHODS 
Enzymatic studies were performed in intact WBCs, cultured fibroblasts, and 
liver and muscle homogenates, obtained at biopsy. Pyruvate oxidation rate 
and citric acid cycle activity in leukocytes and fibroblasts were determined by 
measuring the 14C02 production from pyruvate labeled with carbon 14 in the 
No. 1 position and pyruvate labeled with carbon 14 in the No. 2 position, 
respectively, as described by Willems et al.7 Pyruvate oxidation rate in a liver-
tissue homogenate was studied by measuring the rate of l4CO production 
from [l-14C]pyruvate (Willems et al8). In the same liver homogenate, pyru-
vate carboxylase activity was measured as described by Utter and Keech,9 
with a regenerating system for acetyl-CoA according to Henning and Seu-
bert.10 Pyruvate and 2-oxoglutarate oxidation rate and citric acid cycle 
activity in muscle tissue homogenate were studied by measuring the 14C02 
production from [l-14C]pyruvate, [l-14C]2-oxoglutarate, and malate uni-
formly labeled with carbon 14, respectively, as described by Bookelman et 
al" for isolated muscle mitochondria. Cytochrome oxidase activity in muscle 
homogenate was measured according to the method of Cooperstein and 
Lazorow.12 Muscle carnitine content was assayed in the same homogenate 
according to the method of Parvin and Pande.13 Cytochromes in isolated 
muscle mitochondria from autopsy material were assayed according to 
methods of Bookelman et al.14 Protein was assayed according to the method 
of Lowry et al.15 
RESULTS 
The 14C02 production rate from [l-14C]pyruvate and from [2-14C]pyruvate 
was normal in leukocytes and cultured fibroblasts (table 1). The 14CO 
production rate from [l-14C]pyruvate was decreased in liver homogenate 
(table 1). Pyruvate carboxylase activity in liver homogenate was normal (38.9 
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Table 1. Production of 1 4 C 0 2 In leukocytes, cultured fibroblasts, and liver and muscle 
tissue of patient and controls*. 
Leukocytes1 
Fibroblasts2 
Liver tissue2 
Muscle tissue2 
Substrate 
[1-"C] pyruvate 
[2-14C] pyruvate 
[1-"C] pyruvate 
[2-MC] pyruvate 
[ Ι - ' ΐ ] pyruvate + malate 
[ l- 'C] pyruvate + malate 
[1-"C] pyruvate + carnitine 
Malate '4C [ul| + pyruvate + malonate 
Malate "С [ui] + acetyl-carnitine + malonate 
[1-"C] 2-oxoglutarate 
Patient 
2 21 
2 10 
28 6 
26 9 
19 1 
98 
100 
2% 
41 
105 
Controls 
Range 
140-6 50 
1 40-5 70 
25 2-67 5 
21 1-34 6 
45-205 
243^48 
282-608 
228-546 
279-648 
261-552 
No 
20 
20 
23 
13 
9 
7 
7 
7 
7 
4 
'Production from pyruvate labeled with carbon 14 in the No 1 position and pyruvate labeled with carbon 14 in the 
No 2 position, also from malate uniformly labeled with carbon 14 and 2-oxoglutarale labeled with carbon 14 in the 
No 1 position Malonate was added to incubations with malate MC (ul) to prevent recycling of malate through the 
cycle 
1
 nmole "CO/br/Mf leukocytes 
2
 nmole 14CO /hr/mg protein 
nmole/min/mg protein; controls: 35.0 ± 15.4 nmole/min/mg, mean ± SD; 
η = 6). The 1 4C0 2 production from [l-14C]pyruvate, [l-uC]2-oxoglutarate, 
and especially from malate 14C (ul) in muscle homogenate was decreased 
(table 1), whereas a normal cytochrome oxidase activity was found (69 
nmole/min/mg protein; controls: 53.6 ± 31.3 nmole/min/mg, mean ± SD; 
η = 11). The total amount of carnitine (carnitine + acylcamitines) in 
muscle homogenate was slightly decreased (46.2 nmole/mg protein; controls: 
83 ± 22 nmole/min/mg, mean ± SD; range, 65 to 128 nmole/min/mg; η = 
7). The contents of cytochrome b and cytochrome с + с in muscle mitochon­
dria were slightly decreased; the amount of cytochrome aa3 was within 
normal range (table 2). 
COMMENT 
We have described an infant with a severe and rapidly progressive neurologic 
disorder, being exacerbated during infections, and characterized by psycho­
motor retardation, tetraparesis with ataxia, and myoclonic jerks. Clinical 
signs, EEG, and somatosensory evoked potentials suggested diffuse involve­
ment of gray matter. Laboratory studies showed elevated levels of lactate in 
CSF. The histopathologic abnormalities found in the cerebral hemispheres 
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Table 2. Cytochrome Ь, cytochrome с + с,, and cytochrome аа3 In mitochondria from 
muscle tissue of patient and controls. 
Controls 
Patient (n = 14) 
Cytochrome b* 156 228-^24 
Cytochrome с + с,* 182 365-923 
Cytochrome aa^ 305 271-543 
* pmole/mg protein 
and cerebellum can be classified as a progressive infantile poliodystrophy 
(Alpers' disease). 
Biochemical studies showed no abnormalities for pyruvate metabolism in 
leukocytes and cultured fibroblasts; in liver tissue, normal values were found 
for pyruvate carboxylation, but here pyruvate oxidation was decreased. In 
muscle tissue we found severe disturbances of pyruvate oxidation and of the 
citric acid cycle. 
Parallel incubations of muscle tissue with [l-14C]pyruvate plus either malate 
or carnitine, as an acceptor of acetyl-CoA, will demonstrate such disturban­
ces of the pyruvate oxidation and enable us to tell whether the decreased 
pyruvate oxidation is the result of some defect in the pyruvate dehydrogenase 
complex or of some defect of the citric acid cycle. In the latter case, with 
carnitine a normal 1 4 C 0 2 production from [l-14C]pyruvate should be found. 
In muscle tissue of our patient, 1 4 C0 2 production from [l-14C]pyruvate was 
decreased in the presence of both malate and carnitine. Hence, the faulty 
pyruvate oxidation is not to be attributed to a defect somewhere in the citric 
acid cycle. 
Parallel incubations of human muscle tissue with malate 14C (ul) plus either 
pyruvate or acetylcarnitine, as a donor of acetyl-CoA, will furnish proof of a 
decreased citric acid cycle activity and tell us whether this reduced activity is 
due to some defect of the citric acid cycle or to some defect in the pyruvate 
dehydrogenase complex. In the latter case, with acetylcarnitine a normal 
14CO production from malate 14C (ul) should be found. In our patient, 14CO 
production from malate 14C (ul) was decreased in the presence of both 
pyruvate and acetylcarnitine. Therefore, the decreased citric acid cycle 
activity is not to be attributed to some defect in the pyruvate dehydrogenase 
complex. 
In addition, 1 4 C 0 2 production from [1-14C] 2-oxoglutarate was also decreased. 
The foregoing findings can only be explained in terms of a disturbance of the 
oxidation of NADH, the common pathway in these processes. 
A slight reduction of the content of the cytochrome b and с + с was 
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observed; in our experience, this reduction cannot account for the severe 
disturbance of the substrate oxidation. The biochemical defect must there-
fore be sought in the electron transport system, especially between NADH 
dehydrogenase and coenzyme Q. The subnormal oxidation rate of pyruvate 
in liver homogenate points to the same disturbance as in muscle homogenate. 
The disturbance in the oxidation of NADH, demonstrated in muscle tissue, 
must have been located in the cell mitochondria; however, by histopathologic 
methods, no signs of mitochondrial myopathy were found in skeletal muscle. 
With regard to the mitochondrial abnormalities in heart muscle, it was 
difficult to differentiate between disturbances appearing during the child's 
terminal state and any préexistent disorders. 
We have found only one report of a similar deficiency in NADH oxidation. 
Morgan-Hughes et al16 reported the cases of two sisters (26 and 23 years old) 
with a mitochondrial myopathy, who were first observed with moderate 
muscle weakness and marked exercise intolerance but no signs of CNS 
involvement. Metabolic studies showed increased blood lactate and pyruvate 
levels during exercise. The CSF concentrations of lactate and pyruvate were 
not measured. Tissue studies gave evidence of a mitochondrial myopathy. 
Biochemical studies of muscle mitochondria in one of the sisters pointed to a 
disorder in respiratory chain activity at the level of the NADH-coenzyme Q 
reductase complex. The report suggests that the deficiency was restricted to 
muscle tissue, whereas our case report would point to a more generalized 
disorder. 
After Alpers' description of progressive infantile poliodystrophy in 193117 
and I960,18 Greenhouse and Neubuerger" and Jellinger and Seitelberger20 
gave a review of the literature, with the principal characteristics of this 
syndrome. Alpers' disease is sometimes associated with biochemical defects, 
suggesting a disturbance in cellular energy metabolism in neurons and/or in 
other tissues. Tommasi et al5 and David et al6 described a child having 
progressive infantile poliodystrophy with loss of activity of pyruvate carboxy-
lase in liver tissue. To our knowledge, there is one report of a patient with a 
pyruvate carboxylase deficiency21 and one of a patient having a pyruvate 
dehydrogenase complex deficiency,22 both cases attended with extensive 
degeneration of cerebral tissue as seen at autopsy. Here a tentative diagnosis 
of progressive infantile poliodystrophy could be made, but there is not 
sufficient evidence on the pathologic changes in the brain to be definite. 
Alpers' disease has also been associated with morphologic abnormalities in 
cell mitochondria. Progressive infantile poliodystrophy with abnormal mito-
chondria (giant forms up to 8 μιη) was described by Sandbank and Lerman23 
and by Suzuki and Rapin.24 Shapira et al3 and Hart et al4 reported cases of 
progressive infantile poliodystrophy with lactic acidemia and mitochondrial 
abnormalities in muscle tissue. 
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Our case shows a combination of progressive infantile poliodystrophy and a 
biochemical defect in muscle and liver tissue, ie, a functional abnormality of 
the mitochondria. Surprisingly, no structurally abnormal mitochondria were 
seen in these tissues. Though we have little explanation, their association 
may be more than a coincidence. The elevated level of lactate in CSF, with 
normal serum values, might suggest a disturbed pyruvate metabolism in the 
CNS; appropriate studies excluded other causes of lactate elevation in CSF, 
eg, cerebrovascular and infectious diseases. It is our opinion that a distur-
bance of NADH oxidation in several organ systems, located in the cell 
mitochondria, was the principal factor in the present case of progressive 
infantile poliodystrophy. 
Shapira et al25 have proposed the concept of mitochondrial encephalo-
myopathies, grouping together various neuromuscular disorders with structu-
rally and/or functionally abnormal mitochondria in brain and/or in muscle. 
Our case seems to support such a view. However, we must disagree with their 
statement that there is a specific defect in the oxidative metabolism of the 
various mitochondrial encephalomyopathies. It is our opinion that different 
pathologic patterns can be associated with any kind of biochemical abnorma-
lity in pyruvate metabolism. 
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CHAPTER 5 
PROGRESSIVE INFANTILE POLIODYSTROPHY (ALPERS' 
DISEASE) WITH A DEFECT IN CITRIC ACID CYCLE 
ACTIVITY IN LIVER AND FIBROBLASTS 
MJJ Prick, FJM Gabreëls, WO Renier, JMF Trijbels, JL Willems, 
AJM Janssen, JL Slooff, JAG Geelen and JP de Jager 
Neuropediatrics 13:108-111, 1982 
ABSTRACT 
We present the case history of a boy, who died at the age of З'/г years after a 
rapidly progressive neurologic disorder, characterized by psychomotor retar­
dation, hypotonia, hemiparesis, seizures and myoclonic contractions. Histo­
pathologic studies showed slight lipid storage in liver. Autopsy showed the 
characteristic features of progressive infantile poliodystrophy (Alpers' dis­
ease); ultrastructural examination showed an increased density of mitochon­
dria in cerebral gray matter. Biochemical studies in leukocytes, cultured 
fibroblasts and liver indicated a deficiency in the citric acid cycle between 
succinate and fumarate; this deficiency was not present in muscle tissue. 
This study supports the view that progressive infantile poliodystrophy is 
associated with abnormalities in pyruvate metabolism and/or in cell mito­
chondria. 
KEY WORDS 
Progressive infantile poliodystrophy - Diffuse cerebral sclerosis - Citric acid cycle -
Liver - Lactates - Mitochondria 
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INTRODUCTION 
Progressive infantile poliodystrophy (Alpers' disease) is a rapidly progressive 
autosomal recessive neurologie disorder in children. The clinical picture 
shows psychomotor retardation, epileptic manifestations, myoclonic jerks, 
visual disturbances, ataxia, hypotonia and paresis, which sometimes leads to 
spasticity. These clinical manifestations are provoked or increased by infecti­
ous diseases or other tense circumstances. Many of these children are quickly 
fatigued. Complaints start at 1-3 years, and usually the children die when 
they are between the ages of 2-6 (Alpers 1931, 1960, Greenhouse and 
Neubuerger 1964, Jellinger and Seitelberger 1970, Partouche 1977). 
At present the definite diagnosis of Alpers' disease can only be made by 
histologic examination of the cerebral cortex, presenting neuronal degenera­
tion, gliosis and spongiosis. 
Enzymatic studies in various tissues are of great importance in studying 
diseases with unknow etiology (Di Mauro 1979). Previously three patients 
have been reported with progressive infantile poliodystrophy and a defect in 
pyruvate metabolism, in liver (Tommasi et al 1977), muscle (Prick et al 
1981b) and brain (Prick et al 1981a). This study presents another case, with a 
defect in the citric acid cycle in liver, leukocytes and cultured fibroblasts; this 
defect has not yet been described in connection with Alpers' disease. 
CASE REPORT 
Our patient, a 3-year-old boy, was the younger child of healthy, non-
consanguineous parents. His 6-year-old brother was in good health and the 
family history was unremarkable. His prenatal, natal and postnatal histories 
were unremarkable until he had a febrile convulsion at the age of 2 years. At 
the age of 2/2 the parents complained of a lag in the development of motor 
skills and speech. Physical examination showed moderate psychomotor 
retardation at that time. The electroencephalogram (EEG) was considered 
normal. When З/2 years old, the child had a generalized seizure. Three 
months later he was admitted to our clinic because of another seizure, 
persisting loss of consciousness and continuous myoclonic contractions. The 
boy was stuporous and slightly cyanotic, he frequently vomited and had 
tachycardia and irregular respiration. Head circumference was relatively 
small (49 cm, Рг.з), height and weight were normal. There were general 
hypotonia, paresis and areflexia; atypical and dysrhythmic myoclonic con­
tractions occurred almost continuously. Fundoscopy revealed bilateral optic 
atrophy. Although some improvement occurred, the clinical course remained 
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characterized by hypotonia, myoclonic contractions, impairment of consci-
ousness and intermittent respiratory disturbances. After two months the boy 
became comatose and died due to respiratory arrest. 
Roentgenograms of thorax and skull, as well as carotid and vertebral artery 
angiograms showed no abnormalities; computed tomography of the head 
showed symmetric and slight enlargement of the lateral ventricles, with 
normal third and fourth ventricles, and no cortical atrophy. The electrocardi-
ogram was normal. The EEG showed severe slowing of the background 
rhythm, with generalized paroxysmal discharges and focal sharp waves and 
spikes. Somatosensory potentials evoked by median nerve stimulation show-
ed a normal peak latency of the first complex. However, the secondary 
complex was extremely delayed, suggesting a disorder of cerebral gray 
matter. Brainstem evoked potentials could not be elicited. Visual evoked 
responses were normal. Nerve conduction velocities and electromyograms 
were normal. Normal laboratory tests included: blood count, routine urine 
analysis, renal and hepatic functions, electrolytes, protein and electrophore-
tic pattern, lipid spectrum, creatine kinase, aminoacids in plasma and urine, 
volatile fatty acids in urine, lysosomal enzymes in leukocytes. 
Fasting for 24 hours provoked no hypoglycemia and the subsequent mobiliza-
tion of free fatty acids was normal. Appropriate tests ruled out the presence 
of endocrinologie, immunologic and chronic infectious diseases, vitamine 
deficiencies and poisoning. The analysis of cerebrospinal fluid (CSF) showed 
normal cell count, protein electrophoresis and immune-electrophoresis, but 
elevated total protein content (1050 to 1400 mg/1). Pyruvate levels in serum, 
and lactate levels in serum and urine were elevated. CSF pyruvate and lactate 
values were normal when the child was in a rather good condition; however, 
when comatose, a slight elevation of CSF pyruvate and a severe elevation of 
CSF lactate were observed, with increased lactate/pyruvate ratio. In urine 2-
oxoglutarate and succinate levels were elevated (table 1). 
HISTOPATHOLOGIC STUDIES 
The light microscopic, histochemical and electron microscopic studies of a 
soleus muscle biopsy demonstrated no pathologic alterations. Light micro-
scopy of a liver biopsy only showed some lipid storage in the hepatocytes. 
Cerebral tissue, obtained 3 hours after death, was studied by light and 
electron microscopy. The coronal sections of the brain showed a narrowing 
of the cortex with foci of spongy degeneration (figure 1). Light microscopic 
examination of the cerebral gray matter revealed focal degeneration in all 
cortical layers, characterized by marked degeneration and loss of neurons, 
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Table 1. Lactate and pyruvate values In serum and CSF, and lactate, 2-oioglutarate and 
succinate values In 24-hour urine of patient and controls. 
Lactate" 
Pyruvate" 
Ratio UP 
Lacate" 
2-Oxoglutarateô 
Succinate0 
scrum 
CSF 
serum 
CSF 
serum 
CSF 
unne 
urine 
urine 
I 
1 
I 
(24 h) 
(24 h) 
(24 h) 
conscious 
1850 
1500 
137 
126 
13.5 
119 
Patient 
650-730 
137 
700 
comatose 
1760 
3880 
140 
148 
12.6 
26.0 
Controls 
(n = 200) 
600 -1200 
1200 -1600 
75 - 120 
90 - 130 
6 - 1 0 
11 0- 14.5 
< 100 
< 125 
< 100 
" nmol/l 
0 μιηοΙ/mmol creatinine 
δ μιηοΙ/24 h 
together with considerable proliferation of astrocytes, spongiosis and dilata­
tion of capillaries, among areas with a completely normal cortical structure. 
The degenerative areas appeared to be distributed at random. Neuronal loss 
and gliosis also occurred in the globus pallidus and in some brainstem nuclei. 
Extensive degeneration of Purkinje cells and granular cells accompanied by 
extensive glial proliferation was observed in the cerebellar cortex. At elec­
tron microscopic examination of the cerebral gray matter the major part of 
neuronal and astrocytal mitochondria was swollen, but no specific abnormali­
ties were seen. The cerebral capillaries seemed quite normal, but the 
perivascular spaces were extremely enlarged and occupied by some striking 
membrane bound structures with the same size and shape as mitochondria. 
They mainly consisted of a very dense part, surrounding several oval or 
tubular structures of much lower density (figure 2). 
BIOCHEMICAL STUDIES 
MATERIALS AND METHODS 
Enzymatic studies were performed in intact leukocytes, cultured fibroblasts, 
and homogenates of liver and muscle biopsies. 
Pyruvate oxidation rate and citric acid cycle activity in leukocytes and 
fibroblasts were determined by measuring 1 4C02 production from [l-14C]py-
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Figure 1. Part of coronal section of the brain, showing narrowing of the cortex with foci 
of spongy degeneration. The white matter shows a normal aspect. 
Figure 2. Electronmlcrograph of an abnormal mitochondrion in cerebral gray matter. 
Note the dense granular matrix and the small areas of lower density. B, basal lamina; P, 
perivascular space (Original magnification χ 68000). 
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ruvate and [2-14C]pyruvate respectively (Willems et al 1978). In liver tissue 
homogenate pyruvate oxidation rate and citric acid cycle activity were 
studied by measuring the , 4 C0 2 production from [l-^CJpyruvate, and 
[6-14C]citrate, [1-14C] and [5-14C]2-oxoglutarate respectively (Willems et al 
1977); pyruvate carboxylase activity was also determined (Utter and Keech 
1963), with a regenerating system for acetyl-CoA (Henning and Seubert 
1964). 
Pyruvate oxidation rate and citric acid cycle activity in muscle homogenate 
were studied by measuring the , 4C0 2 production from [l-14C]pyruvate, and 
from [U-14C]malate, [1-14C] and [5-14C]2-oxogIutarate respectively as descri­
bed by Bookelman et al (1978b) for isolated mitochondria. 
Cytochrome oxidase activity was determined in liver and muscle homogena-
tes (Cooperstein and Lazorow 1951). Cytochromes were assayed in isolated 
muscle mitochondria (Bookelman et al 1978a). 
Fatty acid oxidation capacity of muscle was studied with [1-14C] and [U-
14C]palmitate in whole muscle homogenates (Van Hinsbergh et al 1980). 
Protein was assayed according to Lowry et al (1951). 
RESULTS 
In leukocytes the 14C02production rate from [l-14C]pyruvate was normal, 
from [2-14C]pyruvate it was slightly decreased, but the ratio of [1-14C]/ 
[2-14C]pyruvate oxidation was increased (table 2). In cultured fibroblasts 
'"Coproduction from [l-14C]pyruvate was normal, but from [2-14C]pyruvate 
it was reduced (table 2). 
In liver homogenate 1 4C02 production from [l-l4C]pyruvate, [6-l4C]citrate 
and [l-14C]2-oxoglutarate was normal, whereas 1 4C02 production from [5-
14C]2-oxoglutarate was severely decreased (table 2). Pyruvate carboxylase 
activity in liver homogenate was normal (20.7 nmol/min.mg protein; con­
trols: 35.0 ± 15.4, mean ± SD, η = 6); cytochrome с oxidase activity was 
in the lower-normal range (11.2 nmol/min.mg protein; controls 37 ± 13, 
mean ± SN, η = 7). The contents of the cytochromes were not measured 
because of an insufficient amount of liver tissue. In muscle homogenate 
1 4C02 production from [l-14C]pyruvate, [U-14C]malate, [1-14C] and [5-14C]2-
oxoglutarate was normal (table 2), with a normal cytochrome с oxidase 
activity (53.2 nmol/min.mg protein; controls: 53.6 ± 31.3, mean ± SD, η 
= 11). The contents of the cytochromes in muscle mitochrondria were 
normal (table 3). Palmitate oxidation capacity, pro gram muscle, was in the 
normal range. 
To summarize: we found abnormalities in leukocytes, cultured fibroblasts 
95 
Table 2. 1 4 C 0 2 production from various substrates In leukocytes, cultured fibroblasts, 
liver and muscle tissue of patient and controls. 
Substrate 
[1-UC] pyruvate 
[2-'4C] pyruvate 
Ratio [ ΐ - ' ΐ ΐ / ρ - ' ΐ ] pyruvate 
[ l - ' C ] pyruvate 
[г-'С) pyruvate 
[l-^C] pyruvate + malate 
[6-MC] citrate + malate 
[1-I4C] 2-oxoglutarate 
[5-,4C) 2-oxoglutarate 
[1-"C] pyruvate + malate 
[1-ИС) pyruvate + carnitine 
[U-I4C] malate + pyruvate + malonale 
[U-^C] malate + acetylcamitine + malonate 
[1- ,4C] 2-oxoglutarate 
[5-,4CJ 2-oxoglutarate 
Patient 
260 
108 
2.40 
14 4 
3 5 
60.1 
128 7 
45.7 
4.3 
539 
510 
572 
494 
541 
36 
Controls 
1 40-6 50 
140-5 70 
1 00-193 
25.2-67 5 
21.1-34.6 
45-205 
115 ; 189 
106 
46;48 
243-44R 
282-608 
228-546 
279-648 
261-552 
30,48;49 
η 
20 
20 
20 
23 
13 
9 
2 
1 
2 
7 
7 
7 
7 
4 
3 
" nmor
4CO
:
/h IO" leukocytes 
0
 nmoll4C02/h mg protein 
Table 3. Contents0 of cytochromes In mitochondria Isolated from muscle tissue of 
patient and controls. 
Patient Controls (n = 14) 
Cytochrome b 400 228-424 
Cytochrome с + c1 639 365-923 
Cytochrome aa% 411 271-543 
0
 pmol/mg protein 
and liver. The results in fibroblasts and leukocytes pointed to a decreased 
citric acid cycle activity. In liver tissue 1 4C0 2 production from [5-14C]2-
oxoglutarate was severely decreased, which also pointed to a defect in the 
citric acid cycle. 
DISCUSSION 
This patient clearly displayed the clinical and histopathological characteris­
tics of progressive infantile poliodystrophy (Alpers' disease). Progressive 
infantile poliodystrophy has been linked to pyruvate carboxylase deficiency 
in liver (Tommasi et al 1977), to a defect in NADH oxidation in muscle 
Leukocytes" 
Fibroblasts" 
Liver" 
Muscle0 
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(Prick et al 1981b) and to a pyruvate dehydrogenase complex (PDHC) 
deficiency in brain (Prick et al 1981a). Moreover, a PDHC deficiency in 
cultured fibroblasts (Strömme et al 1976) and a pyruvate carboxylase defi-
ciency in liver (Atkin et al 1979) were reported in patients with a cerebral 
autopsy, in our view suggestive of progressive infantile poliodystrophy. 
Enzymatic studies in leukocytes and cultured fibroblasts in our patient 
showed a normal 14CO production from [l-14C]pyruvate and a defective one 
from [2-14C]pyruvate, which is indicative of a decreased citric acid cycle 
activity. Enzymatic studies in liver tissue showed only a severely reduced 
14CO production from [5-14C]2-oxoglutarate with normal 14CO production 
from [l-14C]2-oxoglutarate, indicating a defect in the citric acid cycle between 
succinyl-CoA and malate (succinyl hydrolase, succinate dehydrogenase, 
fumarase). In urine lactate, 2-oxoglutarate and succinate excretion were 
increased, this also points to a deficiency in the citric acid cycle. Considering 
the elevation of 2-oxoglutarate and succinate in urine, the defect is most 
probably located before fumarate. In conclusion a defect in the citric acid 
cycle between succinyl-CoA and fumarate was proved in liver and seemed 
probable in leukocytes and cultured fibroblasts. This defect was not present 
in muscle tissue. In literature we did not find a previous report of a similar 
defect of the citric acid cycle. 
Contrary to previous studies concerning Alpers' disease, electron microsco-
pic studies of cerebral tissue in this patient did not reveal the presence of 
giant mitochondria (Suzuki and Rapin 1969), neither accumulation of mito-
chondria with short curved cristae and dense particles at the periphery was 
seen (Sandbank and Lerman 1972). The mitochondrial changes in our 
material consisted of swelling, probably due to post-mortem alterations, and 
of increased density. The latter phenomenon was described previously and 
was attributed to a low metabolic state of the mitochondria (Ghadially 1975). 
Moreover, the increased mitochondrial density might be considered as a 
precursor of mitochondrial pyknosis (Ghadially 1975) and subsequent auto-
phagia, as has been described in Alpers' disease (Sandbank and Lerman 
1972). 
Since ultrastructural (Hart et al 1977, Sandbank and Lerman 1972, Shapira et 
al 1975, Suzuki and Rapin 1969) as well as biochemical mitochondrial 
abnormalities (Prick et al 1981a,b, Tommasi et al 1977) have been demon-
strated in progressive infantile poliodystrophy, a mitochondrial pathogenesis 
of the disease is likely. Also in the present case there is a defect in pyruvate 
metabolism in liver, leukocytes and fibroblasts. We did not have the opportu-
nity to perform biochemical studies in cerebral tissue. However, it is our 
opinion that a defect in pyruvate metabolism in brain is probable in this case 
of progressive infantile poliodystrophy. 
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CHAPTER 6 
PROGRESSIVE POLIODYSTROPHY (ALPERS' DISEASE) 
WITH A DEFECT IN CYTOCHROME aa3 IN MUSCLE: 
A REPORT OF TWO UNRELATED PATIENTS 
MJJ Prick, FJM Gabreëls, JMF Trijbels, AJM Janssen, R le Coultre, 
К van Dam, HHJ Jaspar, EJ Ebels and AAW Op de Coul 
Clin Neurol Neurosurg 85:57-70, 1983 
ABSTRACT 
We present two unrelated patients, a boy and a girl, with a progressive 
neurologic disorder, characterized by psychomotor retardation, seizures and 
paresis, the illness being exacerbated during stressful periods. Lactate levels 
in serum and cereborspinal fluid were elevated in both patients. Histopatho-
logic studies of muscle tissue revealed mitochondrial abnormalities in the 
boy; in the girl, slight neuronal degeneration was observed. A cerebral 
biopsy in the girl showed abnormalities compatible with progressive polio-
dystrophy. Autopsy in the boy demonstrated progressive poliodystrophy. 
Biochemical studies in muscle tissue showed a defect of cytochrome aa3 in 
both patients, connected with a defect of cytochrome b in the girl. The 
association of defective pyruvate metabolism and progressive poliodystrophy 
is discussed. 
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INTRODUCTION 
In 1962 Luft et al showed for the first time biochemical evidence of mitochon-
drial abnormalities in a patient with a myopathy. They demonstrated a defect 
in the respiratory control of muscle mitochondria (loosely coupling state) in a 
patient with hypermetabolism of nonthyroid origin. Spiro et al (1970) repor-
ted a patient with a progressive neurologic disease with myopathic and 
neuropathic abnormalities in muscle tissue, associated with a marked reduc-
tion in the cytochrome b content of isolated muscle mitochondria. Di Mauro 
(1979) reviewed mitochondrial myopathies, including myopathies with bio-
chemical abnormalities referring to mitochondrial dysfunction. He proposed 
that a rational classification of these myopathies be based on the identifica-
tion of specific biochemical defects. In addition to describing Spiro's patient, 
Di Mauro mentioned 4 reports of a myopathy associated with a deficiency in 
one or two of the cytochromes. He referred to the descriptions by French et 
al (1972), Van Biervliet et al (1977), Morgan-Hughes et al (1977) and 
Willems et al (1977). Di Mauro et al (1980) and recently Heiman-Patterson et 
al (1982) described two other patients with a defect in the cytochromes. 
In this article we report two unrelated patients with a cytochrome aa 
deficiency demonstrated in muscle tissue, in patient 1 associated with a 
moderate deficiency of cytochrome b. Both patients had elevated levels of 
lactate and pyruvate in serum and cerebrospinal fluid (CSF). Histopathologic 
studies on muscle tissue revealed a mitochondrial myopathy in one of them, 
in the other slight myopathic and neuropathic changes were seen. Histopa-
thologic studies on brain tissue showed degeneration of cerebral gray matter, 
indicating a progressive poliodystrophy (Alpers' disease). 
Progressive poliodystrophy is a neurologic disorder with autosomal recessive 
inheritance (Alpers, 1931 and 1960). A definite diagnosis can only be made 
by microscopic study of brain tissue, at autopsy or in a brain biopsy specimen. 
The histopathologic characteristics of progressive poliodystrophy are neuro-
nal degeneration, glial proliferation, capillary dilatation and proliferation, all 
mainly observed in the cerebral gray matter, and to a lesser degree with a 
more varying pattern in other gray structures in the central nervous system 
(CNS). 
The association of a cytochrome aa3 deficiency in muscle tissue and progres-
sive poliodystrophy has not been described until now. 
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CASE REPORTS 
CASE 1 
Patient 1, a girl, was the first child of healthy, nonconsanguineous parents. 
The family history showed no abnormalities. The girl's prenatal, natal and 
postnatal history was unremarkable. The development of motor skills and 
speech was quite normal. 
At approximately 2 years of age, the child was admitted to hospital because 
of aspecific gastro-intestinal disturbances associated with some weight-loss. 
She made a full recovery within some weeks. At age 2 years and 3 months, 
the child's condition again deteriorated. She was admitted urgently to 
hospital because of a myoclonus status, with loss of consciousness, irregular 
respiration, nystagmoid ocular movements, hypotonia, and generalized are-
flexia. The child received 1.5 mg clonazepam three times a day and appa-
rently recovered. She remained at home for approximately three months 
without further problems. Then, she got a myoclonus status again. Her 
condition progressively grew worse, and at age 2 years and 9 months the girl 
died. During this last period a brain biopsy was performed. 
RADIOLOGIC AND ELECTROPHYSIOLOGIC EXAMINATIONS 
Roentgenograms of chest and skull were normal. Cerebral computed tomo-
graphy at age 2 years and 3 months showed no abnormalities; at age 2 years 
and 9 months generalized edema of the right cerebral hemisphere was seen. 
The electroencephalogram (EEG) showed diffuse bilateral slowing. Moreo-
ver, paroxysmal discharges were frequently observed. Visual evoked potenti-
als (VEP) were severely disturbed. 
LABORATORY DATA 
Normal laboratory tests included: blood count, routine urine analysis, renal 
functions, electrolytes, serum pH, PCO2 a n ^ bicarbonate, serum protein and 
electrophoretic pattern, serum lipid spectrum, creatine kinase, serum copper 
and ceruloplasmin, aminoacids in plasma and urine, volatile fatty acids and 
organic acids in urine, lysosomal enzymes in leukocytes. Appropriate studies 
ruled out endocrinologie, immunologic and chronic infectious diseases, defi-
ciencies, and disorders caused by toxic agents. Hepatic functions were 
intermittently moderately disturbed, subsequently a liver biopsy was perfor-
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Table 1. 
(n=200). 
Serum 
CSF 
Lactate and pyruvate values 
Patient 1 
Patient 2 normal circumstances 
after exertion 
Controls 
Patient 1 
Patient 2 
Controls 
In serum and 
Lactate 
(μιποΐ/ΐ) 
1100-2050 
1100-3500 
3300-5000 
600-1200 
1220-1920 
2550-3890 
1200-1600 
CSF of patients and controls 
Pyruvate 
(цтоі/і) 
84-111 
90-160 
190-235 
75-120 
70-100 
145-178 
90-130 
Ratio 
lactate-pyruvate 
12.5-18.0 
9.0-22.5 
14.5-21.5 
up to 15 
18.0-20.0 
17.5-21.9 
up to 15 
med. The analysis of CSF showed normal cell count and normal protein 
electrophoresis, but elevated total protein content (660-1030 mg/l). 
Studies on glucose metabolism showed no major abnormalities. Lactate and 
pyruvate levels in serum and CSF were within normal ranges or slightly to 
moderately increased, with an increased lactate-pyruvate ratio (table 1). 
CASE 2 
Patient 2, a boy, was the third of five children of healthy, nonconsanguineous 
parents. An older sister had died at the age of 5 years after a short illness with 
generalized paralysis and dysfunction of brain, heart and skeletal muscle. A 
first cousin, the child of his mother's sister, had died at 16 years of age after a 
progressive myopathic disorder. His mother, his mother's sister and his 
grandmother had a severe nerve deafness, which became manifest during 
adulthood. Apart from this, the family history showed no abnormalities. 
The boy's prenatal, natal and postnatal history was unremarkable. At 10 
years of age he got a severe epileptic status. During the years following this 
incident, the boy suffered from some severe relapses and his condition 
gradually deteriorated. Several clinical observations occurred, especially 
during these relapses of the disease. Changing grades of consciousness were 
seen, as well as various central neurovegetative signs. Moreover, the boy 
showed a severe mental deterioration, progressive motor disability with 
severe paresis, ataxia, diffuse muscle wasting, and signs of a polyneuropathy 
with motor, sensory and sympathetic dysfunction. Later on, visual disturban­
ces with a left homonymous hemianopia and deafness were observed. 
Occasional generalized fits occurred. Fundoscopy showd slight bilateral optic 
atrophy with moderate pigmentary degeneration. The clinical signs increased 
or were provoked by physical effort, infectious diseases, and other stressful 
situations, probably as a sign of exercise intolerance. From about 13 years of 
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age the boy's condition progressively grew worse, with severe mental deterio-
ration and motor disability, especially during the periods of relapse. At age 
16 years he died, while suffering a new acute relapse. 
RADIOLOGIC AND ELECTROPHYSIOLOGIC EXAMINATIONS 
Roentgenograms of chest and skull were normal. Pneumencephalography 
showed no abnormalities. The electrocardiogram (ECG) was normal. The 
EEG showed severe slowing of the background rhythm. Frequent generali-
zed paroxysmal discharges were seen, with a right occipital epileptic focus. 
Electromyography and nerve conduction velocities showed decreased motor 
and sensory nerve conduction velocities, indicating a polyneuropathy (pero-
neal nerve: motor conduction velocity 33 m/s (normal > 45 m/s), distal 
latency 6.0 ms (normal < 5.0 ms). 
LABORATORY DATA 
Similar laboratory tests were performed as in case 1 ; no specific abnormali-
ties were seen. The analysis of CSF showed a normal cell count, protein 
electrophoresis and immune-electrophoresis, but elevated total protein con-
tent (650 mg/1). 
Studies on glucose metabolism in both serum and CSF showed normal to 
increased levels of lactate and pyruvate, with an increased lactate-pyruvate 
ratio, the elevation being most pronounced after exertion (table 1). 
HISTOPATHOLOGIC STUDIES 
Histopathologic studies were performed on liver and skeletal muscle in both 
patients, and on peripheral nerve in patient 2. All specimens were obtained 
by biopsy. In addition, histopathologic studies were performed on CNS 
tissue: in patient 1 a brain biopsy was performed, in patient 2 CNS tissue was 
studied at autopsy. Unfortunately, an autopsy was not permitted on patient 
1. In patient 1 all biopsies were performed at about TA years of age, in 
patient 2 at 14 years of age. The parents of both patients gave their informed 
consent. 
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Figure la. Transverse section of quadrlcpes muscle. In Gomorl's modified trlchrome 
reaction "ragged-red fibers" are seen. 
LIVER 
Light microscopic studies in both patients, and electron microscopic studies 
in patient 2, showed no major abnormalities. In patient 1, some inflammatory 
infiltrates were present, indicating hepatitis. In patient 2, fatty liver degene-
ration was observed. 
SKETETAL MUSCLE 
Light microscopic, histochemical and electron microscopic studies were 
performed on quadriceps muscle. 
Case 1. Increased variability of muscle fiber diameter was observed, without 
loss of the usual checker-board pattern. These observations indicate focal 
neuronal degeneration without clear nerve cell regeneration. 
Case 2. Increased variability of muscle fiber diameter was observed, caused 
by some focal muscle fiber atrophy. No fiber splitting was observed. There 
was also some type grouping (loss of the usual checker-board pattern), 
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indicating neuronal de- and regeneration. In Gomori's modified trichrome 
reaction "ragged-red fibers" were seen (figure la). These abnormally red-
staining subsarcolemmal areas were also positive for succinic dehydrogenase, 
which is a mitochondrial marker. This activity indicates subsarcolemmal 
aggregation of mitochondria. Electron microscopic studies revealed an 
aggregation of mitochondria in the subsarcolemmal area. Many of these 
mitochondria were enlarged and contained paracrystalline inclusions, someti-
mes dense inclusions. In the muscle fibres too may fat droplets were seen. 
These abnormalities are concordant with the histopathologic characteristics 
of a mitochondrial myopathy (figure lb). 
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PERIPHERAL NERVE 
Light and electron microscopic studies of a sural nerve biopsy taken from 
patient 2 showed the characteristics of a slight neuropathy with axonal loss. 
CENTRAL NERVOUS SYSTEM 
Case 1. Light microscopic studies of brain tissue obtained by biopsy showed a 
distinct lipid storage, in association with slight neuronal degeneration and 
glial proliferation, and moderate capillary dilatation, all restricted to the 
cerebral gray matter. No typical spongiosis was seen. No signs of vascular 
pathology or infectious diseases were observed. Electron microscopic studies 
of the same specimen showed signs of lipid storage predominantly in glial 
cells, and in a lesser amount in neurons. In cerebral white matter no 
abnormalities were observed. In connection with the clinical signs these 
morphologic abnormalities are compatible with progressive poliodystrophy. 
Case 2. Macroscopic observation of the brain, obtained about 24 hours post 
mortem, showed predominantly in the parieto-occipital region at both sides 
and extending from the lateral to the medial surface of the hemispheres, a 
pronounced cerebral atrophy with enlargement of the occipital horn of the 
cerebral ventricles. At section an area with a similar aspect was observed in 
the left cerebellar hemisphere. 
Microscopic studies showed neuronal loss, most pronounced in the 4th and 
5th cortical layers, with glial proliferation, and dilatation and proliferation of 
capillaries. In cerebral white matter some loss of myelin was observed (figure 
2). Similar abnormalities were observed in a small cerebellar region. No 
abnormalities were observed in the mesencephalon, the pons and the 
medulla oblongata. The spinal cord and dorsal root ganglia were not availa-
ble for histopathologic studies. The cerebral arteries showed no abnormali-
ties. No inflammatory signs were seen in the meninges. 
BIOCHEMICAL STUDIES 
MATERIALS AND METHODS 
Biochemical studies were performed on isolated muscle mitochondria and on 
muscle homogenates. Muscle tissue was obtained by a surgical biopsy in both 
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Figure 2. Part of coronal section of the brain, showing the parietal region. Pronounced 
cerebral atrophy with cortical degeneration predominantly In the middle cortical layers. 
Note the sponglous aspect and the Increased number of capillaries. The white matter 
shows a rather normal aspect. 
patients. In patient 1 these studies were performed in 1980 by Trijbels and 
co-workers. Muscle tissue of patient 2 was studied in 1971 by Van Dam and 
co-workers. 
Case 1. Pyruvate and 2-oxoglutarate oxidation rate and citric acid cycle 
activity in muscle tissue homogenate were studied by measuring the 14CO 
production from [l-14C]pyruvate, [l-14C]2-oxoglutarate and [U-14C]malate 
respectively, as described by Bookelman et al (1978b) for isolated muscle 
mitochondria. Cytochrome oxidase activity was measured in a muscle homo-
genate according to the method of Cooperstein and Lazorow (1951). Cyto-
chromes were assayed in isolated muscle mitochondria according to methods 
of Bookelman et al (1978a). Protein was assayed according to the method of 
Lowry et al (1951). 
Case 2. Mitochondria were isolated from muscle tissue using the technique 
described by Hülsmann et al (1969). Cytochrome oxidase activity was 
measured according to Schnaitmann et al (1967). Spectral analysis of cyto-
chromes from isolated muscle mitochondria was performed with and without 
NADH and KCN added. Mitochondria were suspended in 250 mM of 
sucrose, 10 mM of NaCl and 10 mM of MOPS-buffer (pH 7.4). 1 mM of 
NADH and 1 mM of KCN were added. After freezing, spectral analysis was 
performed at the temperature of liquid nitrogen in an Aminco-Chance dual 
wave-length spectrophotometer. 
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RESULTS 
Case 1. 1 4CO production form [l-^CJpyruvate, [l- l4C]2-oxoglutarate and 
[U-14C] malate in muscle homogenate was decreased (table 2). Cytochrome 
oxidase activity was decreased (30.5 nmol/min.mg protein; controls: 73-284, 
η = 36). The contents of the cytochromes in muscle mitochondria were 
decreased, the decrease of cytochrome aa being the most pronounced (table 
3, figure 3). 
Case2. Cytochrome oxidase activity was extremely decreased, approximately 
10% of the reference value. Spectral analysis of the cytochromes showed a 
decrease of cytochrome aa with respect to cytochrome c+c 1 and b (table 
3). 
Table 2. „Coproduction from various substrates In muscle homogenate of patient 1 
and controls. 
1-I4C pyruvate + malate 
1-14C pyruvate + carnitine 
U- 1 4 C malate + pyruvate + malonate 
U- 1 4 C malate + acetylcarnitine + malonate 
l-14C]2-oxoglutarate 
Patient 
(nmol " C O ^ h . 
147 
146 
139 
150 
163 
mg 
Controls 
protein) 
343-448 
282-608 
228-546 
279-648 
261-552 
η 
7 
7 
7 
7 
4 
DISCUSSION 
We reported on two patients with a decrease in the cytochrome aa content in 
isolated muscle mitochondria, associated with progressive poliodystrophy 
(Alpers' disease). Earlier reports on deficiencies in the cytochromes in 
muscle tissue have been made by Spiro et al (1970), French et al (1972), Van 
Biervliet et al (1977), Morgan-Hughes et al (1977), Willems et al (1977), Di 
Mauro et al (1980) and Heiman-Patterson et al (1982). 
Spiro et al (1970) and Morgan-Hughes et al (1977) reported a marked 
reduction of cytochrome b in isolated muscle mitochondria. Histopathologic 
studies on brain tissue were not performed in either of these two cases. Spiro 
et al (1970) described a 16-year-old boy who from the age of approximately 
11 years presented progressive muscular weakness associated with psycho­
motor retardation, epileptic manifestations, myoclonic jerks, ataxia, decrea­
sed visual acuity with chorioretinitis, and areflexia with bilateral extensor 
plantar responses. Lactate and pyruvate studies were not reported. A 
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Table 3. Contents of cytochromes In mitochondria Isolated from muscle tissue of 
patients and controls. 
Cytochrome аа
г 
Cytochrome b 
Cytochrome с + с, 
Patient Г 
89 
131 
310 
Controls* 
(η = 14) 
271-543 
228-424 
365-923 
Patient It Patient 2t Controls, t 
(n = 14) 
03 03 
04 07 
10 10 
07 
05 
1 0 
* Values are expressed as pmol/mg protein 
+ Values of cytochrome аа3 and b for patient 2 are given proportionally to cytochrome с + c, 
for a companson the latter values are also presented for patient 1 and controls 
ΔΑ-0.002 
_J I I I I 
450 500 550 600 650 
Wavelength <nm) 
Figure 3. Difference spectra of human skeletal muscle mitochondria after reduction 
with succinate plus KCN according to Bookelman et al (1978a). The sample cuvette with 
the patient's muscle mitochondria (upper curve) contained 0.22 mg protein. The sample 
cuvette with the control muscle mitochondria (lower curve) contained 0.18 mg protein. 
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skeletal muscle biopsy showed atypical myopathic and neuropathic abnorma-
lities. The father of this patient showed similar clinical and morphologic 
abnormalities. Morgan-Hughes et al (1977) described the case of a 38-year-
old man with progressive muscular weakness and excessive muscular fatigua-
bility dating back to childhood. No mental deterioration or nervous system 
abnormalities were mentioned. A 24-hour urine specimen contained an 
excess of lactate and pyruvate. Serum lactate and pyruvate levels rose sharply 
during exercise. Histochemical studies on muscle tissue indicated a mito-
chondrial myopathy. 
Van Biervliet et al (1977) and Di Mauro et al (1980) reported similar cases: 
patients with a marked reduction of the cytochromes aa and b in isolated 
muscle mitochondria, a disorder clinically resembling the DeToni-Fanconi-
Debré syndrome. The report of Van Biervliet et al (1977) described a child 
with severe neurologic abnormalities, which became apparent during the first 
months of life after an uncomplicated pregnancy and delivery. The clinical 
signs were hypotonia, extreme muscular weakness, lethargy, and the absence 
of visual contact. Laboratory studies revealed renal dysfunction and high 
serum lactate levels. Electron microscopic studies on muscle tissue showed 
large and irregularly shaped mitrochondria, indicating a mitochondrial myo-
pathy. The child died at 13 weeks of age. No autopsy findings were reported. 
Two sisters died at 11 weeks of age after a similar illness. The case report of 
Di Mauro et al (1980) showed a child dying at the age of 15 weeks after an 
illness very similar to that described by Van Biervliet et al (1977). Autopsy 
showed no cerebral abnormalities. Histochemical and electron microscopic 
studies on muscle tissue showed lipid storage and mitochondrial abnormali-
ties. The enzymatic defect could also be demonstrated in kidney tissue. 
Heiman-Patterson et al (1982) described a 8-week-old girl with a clinical 
presentation identical to that of the cases reported by Van Biervliet et al 
(1977) and Di Mauro et al (1980), the child died at 14 weeks of age. A 
skeletal muscle biopsy showed lipid storage and mitochondrial alterations at 
histochemical and electron microscopic studies. Biochemical studies on 
muscle tissue showed a decreased activity of cytochrome-c-oxidase, with 
normal levels of the other mitochondrial enzymes and of carnitine. The 
content of the cytochromes in isolated muscle mitochondria has not been 
mentioned. 
Willems et al (1977) observed a child, having a marked reduction of cyto-
chrome aa content in isolated muscle mitochondria, with subacute necroti-
zing encephalomyelopathy (Leigh disease), proven by autopsy. The disorder 
was characterized by progressive muscular weakness, psychomotor deteriora-
tion, hypotonia, bilateral papillary atrophy, vomiting, respiratory disturban-
ces, and lactic acidemia. The child died at 6 years of age. Histochemical 
studies on muscle tissue revealed no major abnormalities. 
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French et al (1972) described a patient with Menkes' disease (kinky-hair 
disease, trichopoliodystrophy) as having a marked reduction of cytochrome 
aa in mitochondria isolated from muscle tissue obtained by biopsy, and in 
liver and brain tissue obtained at autopsy. The boy died at 21 months of age 
after a progressive neurologic disorder characterized by seizures, psychomo-
tor deterioration, hypotonia, and neurovegetative disturbances. Histopatho-
logic studies on brain tissue showed the characteristics of poliodystrophy in 
the cerebral gray matter, which were associated with the same abnormalities 
in the cerebellar cortex (Purkinje cells) as reported in other patients with 
Menkes' disease. Histochemical studies of muscle tissue showed occasional 
areas of hyaline degeneration. In these regions, electron microscopic studies 
showed disruption of the fine mitochondrial structures. Pathologic findings in 
liver tissue were not reported. In their study from 1972, French et al don't 
mention the values of copper or ceruloplasmin. However, in the same year, 
Danks et al demonstrated that Menkes' disease is due to a defective copper 
metabolism. 
In both patients we described, a marked reduction of cytochrome aa content 
was demonstrated in isolated muscle mitochondria. In patient 1, cytochrome 
b content was decreased to some extent too. The low activity of cytochrome 
oxidase, as measured in patient 1, corresponds positively with the decrease of 
cytochrome aa . The low pyruvate oxidation rate and citric acid cycle activity 
results from a decreased oxidation of NADH in the respiratory chain. In 
patient 2, the enzymatic analysis was restricted to the study of cytochrome 
oxidase activity and of the cytochrome spectrum. The results of that study 
indicate a deficiency in cytochrome aay Comparing these results with the 
results obtained from patient 1, revealed a similar deficiency of cytochrome 
aa in both patients. 
Histopathologic studies on muscle tissue in patient 1 revealed only slight 
neuropathic changes, no abnormal mitochondria were seen. This finding is 
concordant with the findings of Spiro et al (1970), French et al (1972) and 
Ghatak et al (1972). Although biochemical evidence was found for a mito-
chondrial dysfunction, no major mitochondrial abnormalities were seen at 
the microscopic and submicroscopic levels. In patient 2, histopathologic 
studies in muscle tissue showed the characteristics of a mitochondrial myopa-
thy. Van Biervliet et al (1977), Morgan-Hughes et al (1977), Di Mauro et al 
(1980) and Heiman-Patterson et al (1982) also reported concomitant mor-
phologic and biochemical mitochondrial abnormalities in muscle tissue. 
In our two patients we found the histopathologic characteristics of progres-
sive poliodystrophy (Alpers, 1960; Jellinger et al, 1970; Partouche, 1977). 
Unfortunately, autopsy was not permitted on patient 1. However, a brain 
biopsy in this patient indicated progressive poliodystrophy. In patient 2, 
autopsy revealed the well-known characteristics of progressive poliodys-
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trophy, with marked focal diversity in the severity of the pathologic process 
in the various regions of the cerebral cortex. 
In general, progressive poliodystrophy is a disoider of early childhood. The 
clinical signs are progressive psychomotor retardation, seizures, myoclonic 
jerks, hypotonia, paresis, and various other neurologic dysfunctions (Green-
house et al, 1964; Partouche, 1977). The first manifestations of the disorder 
occur mostly at the age of about 1-2 years, the child dies before the age of 5-6 
years, after an illnes with a rapidly progressive course (Greenhouse et al, 
1964; Jellinger et al, 1970; Partouche, 1977). This infantile pattern of 
progressive poliodystrophy was seen in patient 1. Patient 2, on the other 
hand, was a representative of the juvenile form of progressive poliodys-
trophy. This form, manifestating from the age of about 4-8 years, with a 
moderate course, the patients dying approximately between 12-20 years, has 
been reported by several authors (Freedom, 1927; Klein and Dichgans, 1969; 
Guidugli et al, 1973; Shapira et al, 1975; Hart et al, 1977). In patient 2, the 
initial signs were observed at about 10 years; progression was moderate until 
a rather sudden death at 16 years. 
In literature, French et al (1972) report a cytochrome aa deficiency in 
association with poliodystrophy. Their report concerns a child with Menkes' 
disease, a sib of the patient Menkes himself described. Poliodystrophy is a 
common characteristic of Alpers' disease and Menkes' disease, the latter also 
showing cerebellar abnormalities and specific hair abnormalities. Menkes' 
disease is biochemically characterized by a copper deficiency (Danks et al, 
1972). In view of the similarities between Menkes' disease and progressive 
poliodystrophy, it is interesting to know that copper is an important co-factor 
in the cytochrome aa complex. 
In 1975, David et al reported the association of progressive infantile poliodys-
trophy with a pyruvate carboxylase deficiency in liver tissue. In earlier 
communications we reported three cases of progressive poliodystrophy asso-
ciated with a pyruvate dehydrogenase complex deficiency in brain (Prick et 
al, 1981a), with a disturbed NADH oxidation in muscle and liver (Gabreëlset 
al, 1981; Prick et al, 1981b), and with a defect in citric acid cycle activity in 
liver and fibroblasts (Prick et al, 1982). Moreover, a pyruvate dehydrogenase 
complex deficiency in cultured fibroblasts was reported by Strömme et al 
(1976) in a patient whose brain biopsy, in our view, is suggestive of progres-
sive poliodystrophy. In all these cases, elevated levels of lactate and pyruvate 
were found in CSF and/or in serum. 
The combination of progressive poliodystrophy, mitochondrial myopathy 
and lactic acidemia has been reported by Shapira et al (1975) and Hart et al 
(1977). The lactic acidemia may point to a disturbed pyruvate metabolism. 
No enzymatic studies were reported in these cases. 
The number of these reports suggests that there is not a mere casual 
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association, but a causal relationship between progressive poliodystrophy 
(Alpers' disease) and a defect in pyruvate metabolism. It is our opinion that a 
defective cerebral energy metabolism may be a principal etiologic factor in 
the neuronal degeneration of progressive poliodystrophy. 
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CHAPTER 7 
CONCLUSIONS AND DISCUSSION 

SUMMARY OF LITERATURE AND OF PATIENT DATA 
PROGRESSIVE POLIODYSTROPHY IN THE LITERATURE 
In chapter 1 the literature data on 86 cases of progressive poliodystrophy 
were summarized. Progressive poliodystrophy is a pathologic entity characte-
rized by degeneration and loss of neurons, by astrocytic proliferation, and by 
dilatation and proliferation of capillaries. These abnormalities are restricted 
grossly to cerebral gray matter; they occur diffuse in some cases, but have a 
focal distribution in others. Definite diagnosis is only possible by pathologic 
study of brain tissue.19-23 
Progressive poliodystrophy has an autosomal recessive inheritance (McKu-
sick *2037022). The clinical picture is principally that of all progressive 
disorders of cerebral gray matter. The major symptoms of the disorder are 
progressive mental deterioration or retardation, epileptic manifestations, 
myoclonic jerks, and motor disability, manifesting as paresis, hypotonia, 
ataxia. These clinical signs were reported in nearly all reports of the disorder. 
A notable feature is that the symptoms of the disorder were often provoked 
by physical or psychic stress. 
Progressive poliodystrophy was described as a clinical entity for the first time 
by Alpers in 1931.' The clinical signs and the pathologic findings reported in 
the literature by various authors show no major differences from those 
described by Alpers.151619·23 The literature data on progressive poliodys-
trophy make it clear that most of the clinical signs and pathologic features of 
the disorder are now well known. However, little is known about the 
pathogenesis of the disorder. The literature was therefore studied with 
specific emphasis on the pathophysiologic concept of progressive poliodys-
trophy. 
PATHOGENETIC CONCEPTS IN THE LITERATURE 
The discussion as to whether progressive poliodystrophy can be considered as 
a nosologic entity was summarized in chapter 1. With respect to this question 
several pathogenetic concepts were proposed in the literature. Some impor-
tant pathogenetic concepts will be summarized and discussed here. 
Most authors, with Alpers2 as a representative of this group, avoided the 
discussion on the pathogenesis of progressive poliodystrophy. Distinct positi-
ons in the problem of the pathogenesis were adopted by Greenhouse and 
Neubuerger16 and by Jellinger and Seitelberger.19 Greenhouse and Neubuer-
ger stated that cerebral anoxia is the major causal factor of progressive 
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poliodystrophy. In their opinion, periods of cerebral anoxia may occur during 
delivery, during seizures, and possibly also in other situations. Jellinger and 
Seitelberger discussed this proposition that cerebral anoxia could be a causal 
factor in progressive poliodystrophy. They collected from their own material 
and from literature case reports of patients who certainly did not pass 
through periods of cerebral anoxia in such a way that these periods could 
account for a progressive poliodystrophy. Moreover they pointed to the 
familial occurrence of the disorder. They therefore assumed the existence of 
an "idiopathic form" of progressive poliodystrophy. In their hypothesis a 
metabolic disorder would be a major causal factor of this "idiopathic form" 
of the disease. 
DISCUSSION ON TI IE PATHOGENETIC CONCEPTS: CEREBRAL ANOXIA 
A close scrutiny of the literature data provided some arguments relating to 
the discussion on the pathogenesis of progressive poliodystrophy. The argu-
ments regarding the pathophysiologic concept of the disorder will be discus-
sed here. On the basis of this study it is possible to draw some conclusions, 
which can be used to direct the clinical studies on patients. First, the theory 
on cerebral anoxia, as a major causal factor of progressive poliodystrophy, 
will be discussed from a pathologic and a clinical point of view. 
a. The pathologic picture of progressive poliodystrophy, as seen generally at 
autopsy, is dominated by degeneration and loss of neurons. Several patholo-
gic features are against the theory of a generalized cerebral anoxia as a major 
cause of the disorder. 
- The degeneration of neurons is usually fairly obvious, while other gray 
matter structures are relatively unimpaired.1518·27 
- The pathologic picture is that of a progressive neuronal degeneration. 
Pathologic studies often revealed different stages of neuronal degenera-
tion.119 A period of cerebral anoxia generally occurs only once, and is 
therefore not sufficient to account for the pathogenesis of progressive 
poliodystrophy. 
- The pathologic features are often focally distributed, and restricted to 
cerebral gray matter.1519,32 In several cases these features are not present in 
the hippocampal regio, which is very sensitive, especially in generalized 
cerebral anoxia.919,26 
- A swelling and proliferation of endothelial cells in the cerebral capillaries 
is characteristic for cerebral anoxia. This feature was not described in 
progressive poliodystrophy. 
b. Some aspects of the clinical picture also do not accord with the theory of a 
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generalized cerebral anoxia as a major cause of progressive poliodystrophy. 
- The disorder is often inherited as an autosomal recessive trait.22 The 
expression of such a genetic defect is usually that of a primary or secondary 
enzymatic deficiency. 
- The clinical symptoms develop gradually, in such a way that the disorder 
has a progressive course, which in the juvenile form may even be slowly 
progressive.1517·27 An anoxic period would be more likely to cause an acute 
deterioration. 
- A remarkable clinical feature in many cases is that the first symptoms of 
the disease manifest after physical or psychic stress, or that the disorder has 
an exacerbation after stress, for instance after febrille illnesses. Normally 
such periods are not associated with severe anoxia in the descriptions. 
From the aforegoing it may be concluded that it is unlikely that cerebral 
anoxia is a major causal factor of progressive poliodystrophy. 
DISCUSSION ON THE PATHOGENETIC CONCEPTS : METABOLIC DYSFUNCTION 
This literature study provides two important arguments in support of the 
hypothesis of Jellinger and Seitelberger," which suggests that a metabolic 
disorder is perhaps the main causal factor of progressive poliodystrophy. 
a. In many clinical descriptions of progressive poliodystrophy it was reported 
that the first symptoms of the disorder or the exacerbations occurred after 
physical or psychic stress. This clinical feature could be an argument for the 
hypothesis of the metabolic pathogenesis of progressive poliodystrophy. 
During hospital observations it was noticed that the lactate and pyruvate 
levels in serum, urine and CSF were more greatly increased after exertion 
and after glucose or lactate load.23,27 Physical stress normally results in a 
greater demand for ATP, which is produced by means of an increased 
glycolysis. Both in physical stress and during a glucose loading test there is an 
increased load of the pyruvate metabolism. A dysfunction of the pyruvate 
metabolism causes a shortage of ATP and an increase of lactate, the latter 
possibly leading to lactic acidosis. The caracteristic clinical feature that 
symptoms occur or exacerbate after stress may point to a marginal capacity of 
the pyruvate metabolism in these patients. 
The observation of Greenhouse and Neubuerger16 that a period of cerebral 
anoxia was often reported in patients with progressive poliodystrophy does 
not contradict the hypothesis of a metabolic disorder. Cerebral anoxia may 
possibly be such a stress to these children that the first symptoms of the 
disease or the exacerbations can be provoked by a period of anoxia. If the 
pyruvate metabolism has a marginal capacity in these patients, cerebral 
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anoxia may have such serious consequences. This could explain the fact that 
cerebral anoxia was so often reported in association with progressive polio-
dystrophy. 
b. A second important argument for a metabolic pathogenesis of progressive 
poliodystrophy can be found in the outcome of biochemical and pathologic 
studies of some patients described in the literature. Progressive poliodys-
trophy was reported several times in association with a lactic acide-
mia. 17·23·26·27 Moreover, morphologic studies on tissues in patients with the 
disorder revealed abnormal mitochondric in muscle.17·27 and in the brain.26,29 
Two authors reported on patients in whom both a lactic acidemia and a 
morphologically abnormal mitochondria in muscle tissue were found.17,27 
These clinical, biochemical and morphologic findings in patients with pro-
gressive poliodystrophy indicate a metabolic disorder, namely a dysfunction 
of the mitochondrial pyruvate metabolism. 
Enzymatic studies on tissues were performed in only one patient with 
progressive poliodystrophy. Partouche23 described a child with a lactic acide-
mia, and the characteristics of progressive poliodystrophy at autopsy. In liver 
tissue, obtained at autopsy, a severely decreased activity of pyruvate carboxy-
lase was found. It is questionable, however, whether the measurement of the 
labile pyruvate carboxylase in liver tissue obtained after death is sufficiently 
reliable. Partouche did not mention whether, as a control, he studied tissue 
also obtained at autopsy or at biopsy. 
These findings can be an important starting-point for patient studies on the 
pathogenetic mechanism of progressive poliodystrophy. 
THE CEREBRAL ENERGY METABOLISM 
The pyruvate metabolism is particularly important for a properly functioning 
central nervous system (figure 1). Pyruvate -derived from glucose- is the 
main substrate of cerebral energy metabolism. In the citric acid cycle, acetyl-
CoA -derived primarily from pyruvate- is oxidized to C02 . Reducing 
equivalents are made available for ATP synthesis in the electron transport 
chain (respiratory chain). Cerebral pyruvate metabolism is identical to that in 
other tissues, but it is of special significance, since the brain depends entirely 
on the oxidation of pyruvate. It can also utilize ketone bodies when their 
concentration in the blood rises to a certain level, but this is unusual. Thus, as 
far as energy metabolism is concerned, the brain normally depends more than 
other tissues on continuous oxidative decarboxylation of pyruvate. Because 
of this dependency, abnormalities of pyruvate metabolism can reasonably be 
expected to impair the function of the central nervous system.8,30 
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Figure 1. Pyruvate oxidation, citric acid cycle and respiratory chain. 
It is noteworthy that a disturbance of pyruvate metabolism was demonstrated 
previously in several other neurologic disorders. The first report of a neuro­
logic disorder with a defective pyruvate metabolism was that of a 9-year-old 
boy with intermittent ataxia, occurring after a nonspecific febrile illness;5,6 a 
deficiency of pyruvate decarboxylase was demonstrated in muscle tissue and 
in fibroblasts. In the years following, disturbances of pyruvate metabolism 
were reported in patients with various neurologic disorders, especially in 
subacute necrotizing encephalomyelopathy (Leigh's disease)14 and in 
Friedreich's ataxia.20 A few patients with a disturbed pyruvate metabolism 
were also reported with hypomyelination,3 with spinocerebellar degenerati­
ons without further classification,21 and with hereditary motor and sensory 
neuropathy (HMNS I - Charcot-Marie-Tooth).31 Thus, neurologic disorders 
with pathologic abnormalities in various systems and at various levels of the 
nervous system were described in association with disturbances of pyruvate 
metabolism.7 There is probably a causal relationship between these morpho­
logic and biochemical abnormalities. 
To summarize: according to the literature on progressive poliodystrophy the 
pathogenesis of the disorder is still unknown. However, a detailed study of 
the literature data indicates that further investigations of the pathogenetic 
factors of progressive poliodystrophy must include enzymatic studies of the 
pyruvate metabolism and morphologic studies of cell mitochondria. 
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Table 1. Lactate and pyruvate values In serum and cerebrospinal fluid (CSF), and 
lactate, 2-oxoglutarate and succinate values In 24-hour urine of own patients and 
controls. 
Serum 
CSF 
Unne 
Lactate" 
Pyruvate" 
Ratio L/P 
Lactate" 
Pyruvate" 
Ratio L/P 
(24 h) Lactate" 
2-Oxoglutarateò 
Succinate' 
Patient 1 
800 1350 
100 130 
8 0-10 3 
Patient 2 
N 
N 
N 
Patient 3 Patient 4 
1850 1100-2050 
137 84-111 
13 5 12 5-18 0 
Patient 5 
1100-3500 
90-160 
9 0-22 5 
Controls 
600-1200 
75 120 
< 15 
2500 3000 2080 2840 1500-3880 1220 1920 2550 3890 1200-1600 
191-204 
13 1 14 7 
N 
-
— 
N 
19 23 
N 
-
— 
126 148 70 100 
119 26 0 18 20 
650-730 
137 
700 
145 178 
17 5 219 
_ 
-
-
90-130 
< 15 
< 100 
< 125 
< 100 
" μπιοΙ/Ι 
δ μπτιοΙ/ΓΠΓΠοΙ creatinine 
e цтоІ/24 h 
OWN PATIENT DATA 
The conclusions from the literature studies made it probable that abnormali­
ties of pyruvate metabolism could be found in patients with progressive 
pohodystrophy Based on this assumption we carried out biochemical and 
morphologic studies on five children suspected of progressive pohodys­
trophy In these children lactate and pyruvate levels were measured in serum, 
urine and CSF Enzymatic studies of the pyruvate metabolism and morpholo­
gic studies paying special attention to cell mitochondria were performed on 
tissues obtained by biopsies 
Five children with progressive pohodystrophy are reported in this study 
(chapters 3-6)* The clinical signs and the pathologic features in the brain 
tissue of these five children were similar to those described in the literature. 
In all these children clinical manifestations were provoked or increased by 
exertion Routine laboratory studies showed no relevant abnormalities, but 
incidentally moderately disturbed liver function tests 
Metabolic investigations of serum, urine and CSF revealed increased levels of 
lactate and pyruvate in all patients (table 1) In four patients (patients 1, 3, 4, 
5) serum levels of lactate and pyruvate were elevated with a normal to 
slightly increased lactate/pyruvate ratio In one patient (patient 3) the 
excretion of lactate, 2-oxoglutarate and succinate in 24-hour urine was 
increased In all five patients repeated CSF examinations showed increased 
levels of lactate, with normal to moderately elevated pyruvate levels and 
increased lactate/pyruvate ratio 
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Table 2. Results of histopathologic and electron microscopic studies on tissues of own 
patients with progressive pollodystrophy. 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Muscle N lipid myopathy N focal neuronal mitochondrial 
degeneration myopathy 
Liver N lipid storage lipid storage some inflammatory lipid storage 
infiltrates 
Nerve - axonal axonal - axonal 
degeneration degeneration degeneration 
Histochemical and electron microscopic studies of muscle tissue showed no 
abnormalities in two patients (patients 1, 3). In one patient (patient 2) a lipid 
myopathy was observed, in another patient (patient 4) signs of a neurogenic 
muscle atrophy were seen, in yet another patient (patient 5) a mitochondrial 
myopathy was demonstrated (table 2). 
Histochemical and electron microscopic studies of liver tissue revealed slight 
to moderate signs of fatty degeneration (lipid storage) in three patients 
(patients 2, 3, 5). In one patient (patient 4) some inflammatory infiltrates 
were observed. In one patient (patient 1) no abnormalities were seen in liver 
tissue (table 2). 
Enzymatic studies of tissues showed a disturbance of the pyruvate metabo-
lism in all patients (table 3). A deficiency of the pyruvate dehydrogenase 
complex in brain was demonstrated in patient 1, a disturbance in NADH 
oxidation in muscle and liver in patient 2, a decreased citric acid cycle activity 
in liver and fibroblasts in patient 3, and a cytochrome aa deficiency in muscle 
in patients 4 and 5 (table 4, figure 2). 
It is not yet clear whether the decreased enzymatic activity is a primary 
defect, or is due to a disturbance of the regulation of the activity of one or 
more enzymes of the pyruvate metabolism. 
It is remarkable that the enzymatic disturbances demonstrated in tissues, 
indicating a mitochondrial dysfunction, are not always associated with corres-
ponding morphologic abnormalities of mitochondria. This phenomenon is 
known in the literature; Di Mauro1112 described it in mitochondrial myopa-
thies. There is no satisfactory explanation of this phenomenon in the litera-
ture. 
* The patients are numbered here as follows: patient 1 was described in chapter 3, 
patient 2 in chapter 4, patient 3 in chapter 5, patient 4 in chapter 6 as case 1, patient 5 
in chapter 6 as case 2. 
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Table 3. , 4C02 production from various substrates In leukocytes, cultured fibroblasts, 
and liver and muscle tissue of own patients. 
Leukocytes 
Fibroblasts 
Liver 
Muscle 
Substrate 
[1-14C] pyruvate 
[2-14C[ pyruvate 
Ratio [l-14C]/[2-14C] pyruvate 
[1-14C] pyruvate 
[2-,4C] pyruvate 
[1-14C] pyruvate + malate 
[6-14C] citrate + malate 
[1-14C] 2-oxoglutarate 
[5-14C] 2-oxoglutarate 
[1-I4C] pyruvate + malate 
[1-14C] pyruvate + carnitine 
[U-14C] malate + pyruvate + 
matonaie 
[U-14C] malate + acctylcarnitine 
+ malonate 
[1-I4C] 2-oxoglutarate 
[5-14C] 2-oxoglutarate 
Patient 
1 
N 
N 
N 
N 
N 
N 
-
-
_ 
= 
Patient 
2 
N 
N 
N 
N 
N 
I 
~ 
u 
11 
11 
11 
u 
Patient 
3 
N 
N 
Î 
1 
11 
N 
N 
N 
11 
N 
N 
N 
N 
N 
N 
Patient 
4 
-
_ 
-
— 
-
Patient 
5 
-
-
-
— 
-
= 
•f = increased 
1 = decreased 
U = severely decreased 
Table 4. Results of enzymatic studies In leukocytes, cultured fibroblasts, and liver, 
muscle and brain tissue of own patients. 
Leukocytes 
Fibroblasts 
Liver 
Muscle 
Brain 
Patient 1 
N 
N 
N 
N 
PDHC 
deficiency 
Patient 2 
N 
N 
defective 
pyruvate 
oxidation 
defective NADH 
oxidation 
before CoQ 
-
Patient 3 Patient 4 Patient 5 
decreased citric 
acid cycle activity 
decreased citric 
acid cycle activity 
defective citnc 
acid cycle activity 
between 2-oxoglu-
tarate and fumarate 
cytochrome ааз cytochrome aaj 
deficiency deficiency 
- -
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Figure 2. Disturbances In pyruvate oxidation, citric acid cycle and respiratory chain In 
own patient. 
CONCLUSIONS 
In this study five children were reported with progressive poliodystrophy in 
association with morphologic abnormalities in muscle and liver tissue, and 
with a disturbance of pyruvate metabolism demonstrated in one or more of 
the following tissues: brain, muscle, liver or fibroblasts. 
The occurrence of these biochemical abnormalities in five patients with 
progressive poliodystrophy, coupled with the reports in the literature descri­
bing pathologically abnormal mitochondria or a metabolic dysfunction in this 
disease, suggests the existence of a causal relationship between this metabolic 
disorder and this neurologic disease. This association is an important argu­
ment for the existence of a nosologic entity "progressive poliodystrophy", or 
"Alpers' disease". 
This study confirms Jellinger's hypothesis19 of the existence of an "idiopathic 
form" of progressive poliodystrophy caused by a hereditary metabolic dys­
function. The aforegoing does not exclude the possibility that some cases of 
progressive poliodystrophy could be interpreted as a secondary, not heredi­
tary, but symptomatic form of the disease. 
The literature study and the investigations carried out on five patients lead to 
this final conclusion: 
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Progressive poliodystrophy is a neurologic disease of childhood, with a well-
defined clinical picture, an autosomal recessive inheritance, and well-defined 
pathologic features; the disorder is most probably caused by a disturbance of 
the pyruvate metabolism. 
DISCUSSION 
This conclusion gives rise to some questions and reflections, which lead to 
recommendations for further investigations. The following areas will be 
discussed: 
- the diagnostic procedures of the disease 
- carrier detection and antenatal diagnosis 
- possible therapeutic approaches 
- the relation between morphologic and biochemical abnormalities 
- progressive poliodystrophy and neurologic differential diagnosis. 
DIAGNOSTIC PROCEDURES IN PROGRESSIVE POLIODYSTROPHY 
Final diagnosis of progressive poliodystrophy in a child with a progressive 
neurologic disease still requires histopathologic study of brain tissue. In a 
living child a cortical biopsy would be required. To avoid such an invasive 
surgical intervention it would be highly desirable to have less aggressive 
diagnostic procedures. 
On the basis of the reports in the literature and the findings in the five 
patients described above, we are convinced that the diagnosis of "progressive 
poliodystrophy" may be verified by biochemical demonstration of a defi-
ciency in the pyruvate metabolism. 
The decision to perform enzymatic studies on tissues depends very much on 
the results of the determination of lactate, pyruvate and citric acid cycle 
intermediates in serum, urine and CSF. Elevated values may point to a 
disturbed pyruvate metabolism. Other causes of a progressive disorder of 
cerebral gray matter and of elevated levels of lactate and pyruvate must be 
excluded. Thus, infectious diseases, vascular pathology, intoxications, vita-
min déficiences, storage diseases, and inborn errors of metabolism must be 
specifically excluded. 
The question may arise as to whether the elevated values of lactate and 
pyruvate, as found in progressive poliodystrophy, might be the result of or 
appear in connection with the epileptic manifestations occurring in the course 
of the disease, as the result of concurrent cerebral anoxia or acidosis. Our 
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own investigations* revealed that in children with epileptic manifestations 
normal values of lactate and pyruvate were found in serum, urine and CSF, 
even with frequently recurring seizures (e.g. in Lennox-Gastaut seizures). 
An exception is seen in the epilectic status. Therefore it would be implausible 
to state that the elevated lactate and pyruvate levels in progressive poliodys-
trophy are caused by the epileptic manifestations occurring in the disorder. 
Enzymatic studies of tissues must be performed if, on the basis of differential 
diagnostic considerations, a child is suspected of progressive poliodystrophy, 
and the studies of serum, urine and CSF reveal elevated levels of lactate, 
pyruvate, and possibly of citric acid cycle intermediates. In order to find 
morphologic abnormalities, especially abnormal mitochondria, in the same 
tissues microscopic and submicroscopic studies must also be carried out. 
In children clinically suspected of a disorder of the cerebral gray matter, 
lactate and pyruvate levels in serum, urine and CSF constitute a central 
criterion in differential diagnosis. Increased values of lactate and pyruvate 
indicate the possibility of progressive poliodystrophy. As stated earlier in the 
discussion on patient 1 in chapter 3, the study of lactate and pyruvate must 
not be restricted to serum and urine alone, since in many cases the study of 
CSF levels of lactate and pyruvate will be an indispensable diagnostic 
criterion. 
The study of lactate, pyruvate and citric acid cycle intermediates could 
probably be completed by an intravenous lactate23 or pyruvate10 loading test. 
The latter diagnostic procedures appear to be very useful in patients suspec-
ted of progressive poliodystrophy. 
CARRIER DETECTION AND ANTENATAL DIAGNOSIS 
The prevention of progressive poliodystrophy, a severe and rapidly progres-
sive autosomal recessive disorder, requires procedures of carrier detection 
and antenatal diagnosis. 
Carrier detection and antenatal diagnosis are generally performed on cultu-
red fibroblasts, obtained by biopsy or amniocentesis respectively. It therefore 
seems to be important that the results of enzymatic studies on fibroblasts are 
in agreement with those of other tissues. In the present study enzymatic 
studies of fibroblasts were performed in three patients (patients 1, 2, 3). In 
two patients, although there was decreased enzymatic activity in the brain 
(patient 1) and in muscle and liver tissue (patient 2), normal activities of the 
enzymes of the pyruvate metabolism were measured in fibroblasts. In only 
one patient (patient 3) the enzymatic activity of pyruvate oxidation measured 
* Gabreëls, personal communication. 
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in fibroblasts was obviously decreased. From other patient studies it was 
already known that there can be a discrepancy between fibroblast studies and 
studies of other tissues. These findings show that carrier detection and 
antenatal diagnosis by means of fibroblast studies alone may be insufficient at 
this moment. The same problem exists in the study of leukocytes. 
In carrier detection investigations on muscle or even on liver tissue may also 
be performed, but for these studies more invasive procedures are needed. 
Another problem will arise in the several tissue studies, namely that of the 
interpretation of the laboratory data. Biochemical studies of the patients 
described in this study revealed a distinct deficiency in the pyruvate metabo-
lism in fibroblasts, leukocytes, muscle, liver or brain tissue. However, in all 
cases a residual activity was found. In control studies a considerable range of 
the values of enzymatic activity was measured. On theoretical grounds it may 
be virtually impossible to differentiate between patients and carriers, and 
between carriers and normals, because of an overlap of the values of 
enzymatic activity. In our opinion, this problem will arise both in carrier 
detection and in antenatal diagnosis. 
To resolve these problems, further studies of the enzymatic activities of the 
pyruvate metabolism in fibroblasts must be carried out. 
POSSIBLE THERAPEUTIC APPROACHES 
At present progressive poliodystrophy is still an irreversible progressive 
neurologic disease. Therapeutic involvement in the disorder is relevant with 
respect to the relief of symptoms, e.g. epileptic manifestations. It seems 
important to search for a possible causal management of the disease. 
In the literature on progressive poliodystrophy no obvious results concerning 
the causal therapeutic management of the disorder were described. In other 
diseases with similar deficiencies examples of therapeutic management are 
known, e.g. in PDHC deficiency.13,24 and in pyruvate carboxylase deficiency,4 
Therapeutic intervention in patients with a cytochrome related defect ap-
pears to be quite impossible. In disorders with a defective citric acid cycle 
activity, therapeutic management seems to be rather difficult; perhaps the 
addition of citric acid cycle intermediates may be of benefit in such cases. 
With respect to PDHC deficiency Blass7 suggested several possible therapeu-
tic approaches. A high fat diet (ketogenic diet) may provide a substrate that 
bypasses a deficiency located before acetyl-CoA. Thiamine, a cofactor of the 
PDHC system, may favor the activity of PDHC. Dichloracetate is an 
activator of PDHC, and may therefore possibly be profitable in a PDHC 
deficiency. 
It is our opinion that further studies of the therapeutic approaches to 
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deficiencies in pyruvate metabolism, as suggested above, must be performed 
in progressive poliodystrophy. 
THE RELATION BETWEEN MORPHOLOGIC AND BIOCHEMICAL 
ABNORMALITIES 
It has been noted that enzymatic disturbances demonstrated in tissues, 
pointing to a mitochondrial dysfunction, are not always associated with 
corresponding morphologic abnormalities of mitochondria. This observation 
is found in the literature; Di Mauro11 described a similar phenomenon in 
mitochondrial myopathies. A satisfactory explanation of this discrepancy has 
not yet been given in the literature. 
Di Mauro1112 emphasized that the definition of mitochondrial abnormalities 
by morphologic or clinical criteria alone is inadequate. He stressed that a 
rational classification should depend on the identification of the various 
biochemical defects. 
It is our opinion that both biochemical investigations and morphologic 
studies are very important for a better understanding of these functional and 
structural abnormalities of mitochondria. Only combined clinical, morpholo-
gic and biochemical studies will lead to an understanding of the pathogenesis 
of progressive poliodystrophy and of related disorders. 
PROGRESSIVE POLIODYSTROPHY AND NEUROLOGIC DIFFERENTIAL 
DIAGNOSIS 
Until now progressive poliodystrophy was classified in neurologic differential 
diagnosis as a so-called degenerative disorder of the cerebral gray matter, 
without further specification. The addition of biochemical criteria to the well 
known clinical, genetic and morphologic criteria concerning the differential 
diagnosis of neurologic disorders may lead to a new classification of several 
of these "degenerative" neurologic disorders. 
Disturbances of pyruvate metabolism, demonstrated by biochemical studies 
of tissues, may first of all be expected in those disorders, in which histochemi-
cal and electron microscopic studies revealed unexplained abnormalities in 
mitochondria. Disturbances in pyruvate metabolism have already been 
demonstrated in various disorders of the nervous system. Besides progressive 
poliodystrophy some other disorders which are associated with a defect in 
pyruvate metabolism have already been mentioned, e.g. subacute necrotizing 
encephalomyelopathy (Leigh's desease),14 cerebral hypomyelination,3 spino-
137 
cerebellar degenerations,21 Friedreich's ataxia and hereditary motor and 
sensory neuropathy (Charcot-Marie-Tooth disease).31 
Shapira28 grouped together several neurologic and neuromuscular disorders, 
characterized by common morphologic and biochemical abnormalities in 
mitochondria. He proposed calling them "mitochondrial encephalomyopa-
thies". Shapira suggested that these different "mitochondrial encephalomyo-
pathies" would be characterized by morphologic abnormalities in mitochon-
dria and by a specific defect in the oxidative metabolism. 
In the five case reports in our study of progressive poliodystrophy one fairly 
well defined pathologic pattern is associated with various abnormalities in the 
pyruvate metabolism (chapters 3-6). In the literature all these abnormalities 
in pyruvate metabolism were also mentioned in association with other 
neurologic disorders.7 The existence of a specific relation between these 
disorders and the several metabolic defects, as proposed by Shapira,28 
therefore seems unlikely. It seems probable that different disorders of the 
nervous system and neuromuscular disorders can be associated with any kind 
of biochemical abnormalities in pyruvate metabolism. 
Modifying Shapira's hypothesis, we will propose the concept of mitochon-
drial encephalomyeloneuropathy, defined as a primary neuronal dysfunction 
anywhere in the nervous system, caused by a defect in the pyruvate metabo-
lism and sometimes associated with morphologic abnormalities in mitochon-
dria. 
So far, there has not been an adequate explanation of the fact that these 
metabolic disturbances lead to a specific neurologic disorder, with localized 
abnormalities within the nervous system. Some studies indicate that there is a 
differentiated sensitivity of various cerebral areas with respect to the enzy-
mes of pyruvate metabolism.25 However, much more exploratory work must 
be done, with differentiated clinical, morphologic and biochemical studies, 
before we achieve a real insight in the pathogenesis of progressive poliodys-
trophy and other encephalomyeloneuropathies. 
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SUMMARY 
This study summarizes the literature on progressive poliodystrophy in a 
review of 86 cases, and presents the reports of five children with progressive 
poliodystrophy in association with a disturbed pyruvate metabolism. 
Progressive poliodystrophy is a neurologic disorder of childhood with an 
autosomal recessive inheritance. The clinical picture is principally that of all 
progressive disorders of cerebral gray matter. The major symptoms are 
mental retardation or deterioration, epileptic seizures, myoclonic jerks, and 
motor disability. Visual and auditive dysfunctions are also frequently obser-
ved, as well as neurovegetative signs. The symptoms of the disorder are often 
provoked by physical of psychic stress. With respect to the age distribution, a 
distinction must be made between an infantile and a juvenile form of the 
disease. 
The definite diagnosis of progressive poliodystrophy can only be made by 
histopathologic study of brain tissue. The disorder is characterized by dege-
neration and loss of neurons, by astrocytic profileration, and by dilatation 
and proliferation of capillaries. These abnormalities are restricted grossly to 
cerebral gray matter; they occur diffusely in some cases, but have a focal 
distribution in others. 
Neuroradiologic, electroencephalographic and routine laboratory studies 
revealed no specific abnormalities. In several cases in the literature, increa-
sed levels of lactate and pyruvate in serum and in cerebrospinal fluid (CSF) 
were reported. Histochemical and submicroscopic studies of skeletal muscle 
tissue showed abnormalities in mitochondria in several cases. 
The literature data on progressive poliodystrophy are summarized in chapter 
1. In the literature little is known about the pathogenesis of progressive 
poliodystrophy. Two important pathogenetic concepts, proposed in the 
literature, are summarized and discussed in this study. 
The findings of increased levels of lactate and pyruvate in serum and in CSF, 
and the morphologic abnormalities in muscle tissue mitochondria, indicated a 
defect in the intramitochondrial pyruvate metabolism. Some studies on the 
pathogenesis of the disorder supported this hypothesis. Therefore, when 
searching for pathogenetic factors in progressive poliodystrophy, special 
attention was directed to the cerebral pyruvate metabolism. Some biochemi-
cal aspects of the carbohydrate metabolism were summarized in chapter 2. 
The association of defects in the pyruvate metabolism with neurologic 
disorders (e.g. subacute necrotizing encephalomyelopathy and Friedreich's 
ataxia) was reported in the same chapter. 
In four studies (chapters 3-6) extensive clinical, morphologic and biochemical 
investigations of five unrelated patients were reported. They all showed 
clinical symptoms indicating a progressive disorder of cerebral gray matter; 
143 
in all the children the illness exacerbated during stressful periods. Lactate 
levels in serum and/or CSF were elevated in all patients. Histopathologic 
studies of brain tissue showed the characteristics of progressive poliodys-
trophy in all patients. A deficiency of the pyruvate dehydrogenase complex 
in the brain was demonstrated in patient 1*, a disturbance in NADH 
oxidation in muscle and liver in patient 2, decreased citric acid cycle activity 
in liver and fibroblasts in patient 3, and a cytochrome aa deficiency in muscle 
in patients 4 and 5. 
The occurence of these biochemical abnormalities in five patients with 
progressive poliodystrophy, coupled with the reports in the literature descri-
bing pathologically abnormal mitochondria or a metabolic dysfunction in this 
disease, suggests the existence of a causal relationship between this metabolic 
disorder and this neurologic disease. The literature study and the investigati-
ons carried out on the five patients lead to this final conclusion. Progressive 
poliodystrophy is a neurologic disease of childhood, with a well-defined 
clinical picture, an autosomal recessive inheritance, and well-defined patho-
logic features; the disorder is most probably caused by a disturbance of the 
pyruvate metabolism. 
In a final discussion, the diagnostic procedures of the disease, carrier detec-
tion and antenatal diagnosis, possible therapeutic approaches, the relation 
between morphologic and biochemical abnormalities and the relation 
between progressive poliodystrophy and neurologic differential diagnosis are 
discussed (chapter 2). 
patients are numbered as in chapter 7. 
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SAMENVATTING 
Deze studie geeft in een overzicht van 86 gevallen een samenvatting van de 
literatuur over progressieve poliodystrofie, en beschrijft daarnaast 5 kinde-
ren met progressieve poliodystrofie bij wie een stoornis in het pyravaatmeta-
bolisme werd aangetoond. 
Progressieve poliodystrofie is een neurologische aandoening met een autoso-
maal recessieve erfmodus, optredend bij kinderen. Het klinisch beeld is in 
wezen gelijk aan dat van alle progressieve grijze stof aandoeningen. De 
voornaamste kenmerken zijn: mentale retardatie of deterioratie, epilepsie, 
myoclonieën en motorische uitvalsverschijnselen. Daarnaast worden vaak 
stoornissen waargenomen van het gehoor en de visus, evenals neurovegeta-
tieve stoornissen. Lichamelijke of geestelijke stress provoceert dikwijls de 
verschijnselen. Onderscheid moet worden gemaakt tussen een infantiele en 
een juveniele vorm van de ziekte. 
De diagnose "Progressieve Poliodystrofie" kan uiteindelijk alleen gesteld 
worden door histopathologisch onderzoek van hersenweefsel. De aandoe-
ning wordt gekenmerkt door degeneratie en verlies van neuronen, door 
proliferatie van astrocyten en door verwijding en proliferatie van capillairen. 
Deze afwijkingen zijn globaal genomen beperkt tot de cerebrale grijze stof; 
in sommige gevallen treden ze diffuus verspreid op, soms wordt een pleksge-
wijze verdeling gezien. 
Neuroradiologisch, elektro-encefalografisch en routine laboratoriumonder-
zoek tonen geen kenmerkende afwijkingen. In de literatuur werden verschil-
lende gevallen beschreven met verhoogde waarden voor laktaat en pyruvaat 
in serum en liquor. Histochemisch en submikroskopisch onderzoek van 
spierweefsel toonde in verschillende gevallen afwijkende mitochondria. 
De gegevens uit de literatuur zijn samengevat in Hoofdstuk 1. Uit de 
literatuur blijkt dat er weinig bekend is over de Pathogenese van de progres-
sieve poliodystrofie. Twee belangrijke in de literatuur voorgestelde pathoge-
netische concepten zijn in deze studie samengevat en bediscussieerd. 
Zowel de verhoogde waarden voor laktaat en pyruvaat in serum en liquor, 
alsook de morfologische afwijkingen in spiermitochondriën, gaven aanwij-
zingen voor een stoornis in het intramitochondriële pyruvaatmetabolisme. 
Enkele studies over de Pathogenese van de aandoening gaven steun aan deze 
hypothese. Daarom werd in deze studie bijzondere aandacht besteed aan het 
cerebrale pyruvaatmetabolisme. 
Enkele biochemische aspekten van het koolhydraatmetabolisme zijn sa-
mengevat in hoofdstuk 2. Tevens worden in dit hoofdstuk enkele neurolo-
gische aandoeningen vermeld (o.a. subacute necrotiserende encephalomy-
elopathie en de ataxie van Friedreich), waarbij stoornissen in het pyruvaat 
metabolisme aangetoond werden. 
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In de hoofdstukken 3 t/m 6 wordt uitgebreid ingegaan op klinisch, morfolo-
gisch en biochemisch onderzoek bij 5 niet verwante patientjes. Al deze 
patientjes toonden klinische verschijnselen die wezen op een progressieve 
aandoening van de cerebrale grijze stof; bij al deze kinderen trad er een 
verergering van de ziekte op tijdens perioden met stress. Bij deze patientjes 
werden verhoogde waarden voor laktaat gemeten in serum en/of liquor, 
bovendien toonde histopathologisch onderzoek van hersenweefsel de typi-
sche kenmerken van progressieve poliodystrofie. Aangetoond werden: bij 
patientje 1. een deficiëntie van het pyruvaat dehydrogenasecomplex in 
hersenweefsel, bij patientje 2. een stoornis in de NADH oxidatie in spier- en 
leverweefsel, bij patientje 3. een verminderde aktiviteit van de citroenzuur-
cyclus in lever en fibroblasten en bij de patientjes 4. en 5. een cytochroom aa 
deficiëntie in spierweefsel. 
Het optreden van deze biochemische stoornissen in de 5 beschreven 
patientjes, samen met de gegevens uit de literatuur die spreken over patho-
loog anatomisch abnormale mitochondriën, of over een metabole stoornis bij 
deze ziekte, geven sterke aanwijzingen voor het bestaan van een oorzakelijk 
verband tussen de biochemische en de morfologische afwijkingen. 
De bestudering van de literatuur en het uitgevoerde onderzoek leiden tot de 
conclusie: Progressieve poliodystrofie is een neurologische ziekte optredend 
op kinderleeftijd, met een duidelijk omschreven klinisch beeld, een autoso-
maal recessieve erf modus en vaste patholoog anatomische kenmerken. De 
aandoening wordt hoogstwaarschijnlijk veroorzaakt door een stoornis in het 
pyruvaatmetabolisme. 
In de discussie worden de methoden van onderzoek, de carrier detectie en 
prenatale diagnostiek, de mogelijke therapeutische benaderingen, de relatie 
tussen morfologische en biochemische afwijkingen en de samenhang tussen 
progressieve poliodystrofie en de neurologische differentiaal diagnostiek 
besproken. 
146 


WOORDEN VAN DANK 
Dit onderzoek is verricht vanuit de Afdeling Kinderneurologie (Hoofd: Prof. 
Dr. F.J.M. Gabreëls) van het Instituut voor Neurologie (Hoofd: Prof. Dr. 
B.P.M. Schulte) van het Sint Radboudziekenhuis te Nijmegen. 
In dit onderzoek hebben in belangrijke mate bijgedragen de „Nijmeegse 
Interdisciplinaire Werkgroep Kwantitatief Hersenschorsonderzoek" en de 
„Nijmeegse Interdisciplinaire Werkgroep Neuromusculaire Aandoeningen". 
De interesse van de Afdeling Kinderneurologie in de normale en gestoorde 
cerebrale stofwisseling en het daarover reeds jaren lopende onderzoek, 
hebben deze studie mogelijk gemaakt. 
Bijzondere dank ben ik verschuldigd aan de medewerkers van: 
- het klinisch chemisch laboratorium en het klinisch neuropathologisch 
laboratorium van het Instituut voor Neurologie 
- de biochemische afdeling van het klinisch chemisch laboratorium van het 
Instituut voor Kindergeneeskunde 
- het Instituut voor Biochemie van de Universiteit van Nijmegen 
- het Instituut voor Biochemie (B.C.P. Jansen Instituut) van de Universiteit 
van Amsterdam 
- de afdelingen Neuropathologie van de Nijmeegse en Groningse Universi-
teit 
- en de afdeling Submicroscopische Morfologie van de Nijmeegse Universi-
teit, voor hun daadwerkelijke inbreng. 
In het bijzonder wil ik dankzeggen aan de heer A.C. Romsom voor zijn vele 
en zeer deskundige adviezen ten aanzien van de inhoud en de technische 
uitvoering van het proefschrift. 
Tevens wil ik de heer E. de Graaf f van de Medische Bibliotheek danken voor 
zijn hulp bij het verzamelen van de literatuurgegevens en de medewerkers 
van de Foto-, Film- en Tekenafdeling van het Instituut voor Neurologie te 
Nijmegen voor hun inbreng in het totstandkomen van de afbeeldingen. 
Tenslotte wil ik mijn vrouw en kinderen danken voor de ruimte die zij mij 
gaven om in rust aan dit proefschrift te werken. 
149 

CURRICULUM VITAE 
Mathé Prick werd geboren op 17 september 1946 te Nijmegen. Hij volgde 
daar het lager onderwijs en het Gymnasium Beta (Canisius College). Hierna 
begon hij aan de studie filosofie-theologie, resulterend in een vijf jarig 
kandidaats theologie aan de Katholieke Theologische Hogeschool Amster-
dam, 1974. In 1969 begon hij met de studie geneeskunde aan de Universiteit 
van Amsterdam, waar hij in 1976 het artsexamen behaalde. In 1976 begon hij 
zijn opleiding tot neuroloog; de opleiding neurologie volgde hij aan het 
Radboud Ziekenhuis in Nijmegen (opleider Prof. Dr. J.J.G. Prick, later 
Prof. Dr. B.P.M. Schulte), de stage psychiatrie volgde hij in het Academisch 
Ziekenhuis van de Universiteit van Amsterdam (opleider Prof. Dr. P.C. 
Kuiper), de opleiding voor de aantekening klinische neurofysiologie volgde 
hij wederom aan het Radboud Ziekenhuis in Nijmegen (opleiders Prof. Dr. 
S.L.H. Notermans en Drs. P.J.H. Bernsen). De opleiding werd beëindigd op 
31 augustus 1981. Sedert 1 november 1981 is hij werkzaam als neuroloog-
klinisch neurofysioloog aan het Canisius-Wilhelmina Ziekenhuis in Nijme-
gen, in associatief verband met J.J. Prick (tot juli 1983), E.F.J.Poels, en Dr. 
C.W.G.M. Frenken (vanaf juli 1983). Sedert september 1977 is hij als docent 
neurologie/psychiatire verbonden aan de Opleiding Logopedie te Nijmegen. 
151 


